Sanofi (SNY) 6-K29 Jul 202020 Half-year Financial ReportFinancial data

Company Profile

Cover page

Cover page	6 Months Ended
Cover page	Jun. 30, 2020
Entity Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001121404
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2020
Entity Registrant Name	SANOFI

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - EUR (€) € in Millions	Jun. 30, 2020	Dec. 31, 2019
Assets
Property, plant and equipment	€ 9,368	€ 9,717
Right-of-use assets	1,236	1,300
goodwill	45,254	44,519
Other intangible assets	17,021	16,572
Investments accounted for using the equity method	196	3,591
Other non-current assets	3,031	2,667
Deferred tax assets	4,830	5,434
Non-current assets	80,936	83,800
Inventories	8,895	7,994
Accounts receivable	7,203	7,937
Other current assets	2,727	3,253
Cash and cash equivalents	15,969	9,427
Current assets	34,794	28,611
Assets held for sale or exchange	89	325
TOTAL ASSETS	115,819	112,736
Equity and liabilities [abstract]
Equity attributable to equity holders of Sanofi	63,304	58,934
Equity attributable to non-controlling interests	182	174
Total equity	63,486	59,108
Long-term debt	20,404	20,131
Non-current lease liabilities	947	987
Non-current liabilities related to business combinations and to non-controlling interests	413	508
Non-current provisions and other non-current liabilities	9,785	9,321
Deferred tax liabilities	1,976	2,294
Non-current liabilities	33,525	33,241
Accounts payable	4,920	5,313
Current liabilities related to business combinations and to non-controlling interests	243	292
Current provisions and other current liabilities	10,061	9,961
Current lease liabilities	248	261
Short-term debt and current portion of long-term debt	3,329	4,554
Current liabilities	18,801	20,381
Liabilities related to assets held for sale or exchange	7	6
TOTAL EQUITY AND LIABILITIES	€ 115,819	€ 112,736

CONSOLIDATED INCOME STATEMENTS

CONSOLIDATED INCOME STATEMENTS - EUR (€) € in Millions, shares in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Profit (loss) [abstract]
Net sales	€ 17,180	€ 17,019	€ 36,126
Other revenues	574	674	1,505
Cost of sales	(5,543)	(5,385)	(11,976)
Gross profit	12,211	12,308	25,655
Research and development expenses	(2,692)	(2,972)	(6,018)
Selling and general expenses	(4,607)	(4,835)	(9,883)
Other operating income	281	273	825
Other operating expenses	(693)	(466)	(1,207)
Amortization of intangible assets	(883)	(1,116)	(2,146)
Impairment of intangible assets	(323)	(1,840)	(3,604)
Fair value remeasurement of contingent consideration	54	190	238
Restructuring costs and similar items	(758)	(747)	(1,062)
Other gains and losses, and litigation	136	317	327
Gain on Regeneron investment arising from transaction of May 29, 2020	7,382	0	0
Operating income	10,108	1,112	3,125
Financial expenses	(198)	(244)	(444)
Financial income	31	94	141
Income before tax and investments accounted for using the equity method	9,941	962	2,822
Income tax expense	(994)	(13)	(139)
Share of profit/(loss) from investments accounted for using the equity method	354	116	255
Net income excluding the exchanged/held-for-exchange Animal Health business	9,301	1,065	2,938
Net income/(loss) of the exchanged/held-for-exchange Animal Health business	0	0	(101)
Net income	9,301	1,065	2,837
Net income attributable to non-controlling interests	20	15	31
Net income attributable to equity holders of Sanofi	€ 9,281	€ 1,050	€ 2,806
Average number of shares outstanding (in shares)	1,251.7	1,247.2	1,249.9
Average number of shares after dilution (in shares)	1,258.2	1,254.7	1,257.1
Basic earnings per share (in euros per share)	€ 7.41	€ 0.84	€ 2.24
Basic earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share)	7.41	0.84	2.33
Diluted earnings per share (in euros per share)	7.38	0.84	2.23
Diluted earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share)	€ 7.38	€ 0.84	€ 2.31

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Statement of comprehensive income [abstract]
Net income	€ 9,301	€ 1,065	€ 2,837
Attributable to equity holders of Sanofi	9,281	1,050	2,806
Attributable to non-controlling interests	20	15	31
Other comprehensive income:
Actuarial gains/(losses)	(146)	(535)	(382)
Change in fair value of equity instruments included in financial assets	299	34	106
Tax effects	(89)	117	113
Items not subsequently reclassifiable to profit or loss	64	(384)	(163)
Change in fair value of debt instruments included in financial assets	4	28	28
Change in fair value of cash flow hedges	29	(15)	(13)
Change in currency translation differences	(944)	410	751
Tax effects	9	17	47
Items subsequently reclassifiable to profit or loss	(902)	440	813
Other comprehensive income for the period, net of taxes	(838)	56	650
Comprehensive income	8,463	1,121	3,487
Attributable to equity holders of Sanofi	8,451	1,105	3,457
Attributable to non-controlling interests	€ 12	€ 16	€ 30

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - EUR (€) € in Millions		Total	Share capital	Additional paid-in capital	Treasury shares	Reserves and retained earnings	Stock options and other share- based payments	Other comprehensive income	Attributable to equity holders of Sanofi	Attributable to non- controlling interests
Beginning balance at Dec. 31, 2017	[1]	€ 58,239	€ 2,508	€ 58	€ (14)	€ 52,804	€ 3,298	€ (584)	€ 58,070	€ 169
First-time application of IFRS 9		(13)				839		(852)	(13)
Other comprehensive income for the period		959				(305)		1,268	963	(4)
Net income for the period	[1]	4,410				4,306			4,306	104
Comprehensive income		5,369				4,001		1,268	5,269	100
Dividend paid out of earnings		(3,773)				(3,773)			(3,773)
Payment of dividends to non-controlling interests		(97)								(97)
Share repurchase program	[2]	(1,100)			(1,100)				(1,100)
Reductions in share capital		0	(24)	(213)	880	(643)
Share-based payment plans:
Exercise of stock options		59	2	57					59
Issuance of restricted shares and vesting of existing restricted shares	[3]	0	4	(4)	80	(80)
Employee share ownership plan		120	5	115					120
Proceeds from sale of treasury shares on exercise of stock options		1			1				1
Value of services obtained from employees		284					284		284
Tax effects of the exercise of stock options		14					14		14
Other changes arising from issuance of restricted shares	[4]	13				13			13
Change in non-controlling interests without loss of control		(65)				(68)			(68)	3
Change in non-controlling interests arising from divestment		(16)								(16)
Ending balance at Dec. 31, 2018	[1]	€ 59,035	2,495	13	(153)	53,093	3,596	(168)	58,876	159
Share-based payment plans:
Dividend paid per share (in euros per share)		€ 3.03
Other comprehensive income for the period		€ 56				(384)		439	55	1
Net income for the period		1,065				1,050			1,050	15
Comprehensive income		1,121				666		439	1,105	16
Dividend paid out of earnings		(3,834)				(3,834)			(3,834)
Payment of dividends to non-controlling interests		(10)								(10)
Share repurchase program	[2]	(12)			(12)				(12)
Exercise of stock options		44	2	42		0			44
Issuance of restricted shares and vesting of existing restricted shares	[3]	0	7	(7)	153	(153)
Proceeds from sale of treasury shares on exercise of stock options		3			3				3
Value of services obtained from employees		131					131		131
Tax effects of the exercise of stock options		3					3		3
Other changes arising from issuance of restricted shares	[4]	30				30			30
Other	[5]	7				7			7
Ending balance at Jun. 30, 2019		€ 56,518	2,504	48	(9)	49,809	3,730	271	56,353	165
Share-based payment plans:
Dividend paid per share (in euros per share)		€ 3.07
Beginning balance at Dec. 31, 2018	[1]	€ 59,035	2,495	13	(153)	53,093	3,596	(168)	58,876	159
Other comprehensive income for the period		650
Net income for the period		2,837
Comprehensive income		3,487
Ending balance at Dec. 31, 2019		59,108	2,508	147	(9)	51,780	3,863	645	58,934	174
Beginning balance at Jun. 30, 2019		56,518	2,504	48	(9)	49,809	3,730	271	56,353	165
Other comprehensive income for the period		594				222		374	596	(2)
Net income for the period		1,772				1,756			1,756	16
Comprehensive income		2,366				1,978		374	2,352	14
Payment of dividends to non-controlling interests		(4)								(4)
Share-based payment plans:
Exercise of stock options		103	4	99		0			103
Value of services obtained from employees		121					121		121
Tax effects of the exercise of stock options		12					12		12
Change in non-controlling interests without loss of control		(8)				(7)			(7)	(1)
Ending balance at Dec. 31, 2019		59,108	2,508	147	(9)	51,780	3,863	645	58,934	174
Other comprehensive income for the period		(838)				64		(894)	(830)	(8)
Net income for the period		9,301				9,281			9,281	20
Comprehensive income		8,463				9,345		(894)	8,451	12
Dividend paid out of earnings		(3,937)				(3,937)			(3,937)
Payment of dividends to non-controlling interests		(4)								(4)
Share repurchase program	[2]	(361)			(361)				(361)
Share-based payment plans:
Exercise of stock options		38	1	37					38
Issuance of restricted shares and vesting of existing restricted shares	[3]	0	3	(3)	126	(126)			0
Value of services obtained from employees		165					165		165
Tax effects of the exercise of stock options		12					12		12
Other changes arising from issuance of restricted shares	[4]	2				2			2
Ending balance at Jun. 30, 2020		€ 63,486	€ 2,512	€ 181	€ (244)	€ 57,064	€ 4,040	€ (249)	€ 63,304	€ 182
Share-based payment plans:
Dividend paid per share (in euros per share)		€ 3.15

[1]	Includes the effects of first-time application of IFRS 15 on revenue recognition (see Note A.2.1.1. to the consolidated financial statements for the year ended December 31, 2018).
[2]	See Note B.8.2.
[3]	This line includes restricted share awards fulfilled using existing shares.
[4]	Issuance of restricted shares to former employees of the Animal Health business and the European Generics business subsequent to the date of divestment
[5]	This line includes the impact of the settlement of a put option granted to non-controlling interests in connection with a divestment.

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - € / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2018
Statement of changes in equity [abstract]
Dividend paid per share (in euros per share)	€ 3.15	€ 3.07	€ 3.03

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Condensed Cash Flow Statements, Captions [Line Items]
Net income attributable to equity holders of Sanofi		€ 9,281	€ 1,050	€ 2,806
Net (income)/loss of the exchanged/held-for-exchange Animal Health business		0	0	101
Non-controlling interests	[1]	20	15	31
Share of undistributed earnings from investments accounted for using the equity method		(327)	(82)	(192)
Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets		2,013	3,779	7,452
Gains and losses on disposals of non-current assets, net of tax	[2]	(177)	(63)	(286)
Net change in deferred taxes		(296)	(818)	(1,753)
Net change in non-current provisions and other non-current liabilities	[3]	317	(27)	58
Cost of employee benefits (stock options and other share-based payments)		168	131	252
Impact of the workdown of acquired inventories remeasured at fair value		36	3	3
Other profit or loss items with no cash effect		155	(12)	(309)
Operating cash flow before changes in working capital and excluding the exchanged/held-for-exchange Animal Health business		4,320	3,976	8,163
(Increase)/decrease in inventories		(1,023)	(934)	(547)
(Increase)/decrease in accounts receivable		516	90	(462)
Increase/(decrease) in accounts payable		(325)	(49)	169
Net change in other current assets and other current liabilities		438	96	421
Net cash provided by/(used in) operating activities excluding the exchanged/held-for-exchange Animal Health business	[4]	3,926	3,179	7,744
Acquisitions of property, plant and equipment and intangible assets		(682)	(841)	(1,816)
Acquisitions of consolidated undertakings and investments accounted for using the equity method	[5]	(2,360)	(134)	(488)
Acquisitions of other equity investments		(17)	(24)	(38)
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax	[6]	709	867	1,224
Net change in other non-current assets		(87)	(33)	(94)
Net cash provided by/(used in) investing activities excluding the exchanged/held-for-exchange Animal Health business		8,075	(165)	(1,212)
Net cash inflow/(outflow) from the exchange of the Animal Health business for BI’s Consumer Healthcare business		0	0	154
Issuance of Sanofi shares		38	58	162
Dividends paid to shareholders of Sanofi		(3,937)	(3,834)	(3,834)
Dividends paid to non-controlling interests	[1]	(4)	(9)	(14)
Payments received/(made) on changes of ownership interest in a subsidiary without loss of control		0	0	(7)
Additional long-term debt contracted		2,014	1,994	1,997
Repayments of long-term debt		(3,954)	(1,261)	(2,067)
Repayment of lease liabilities		(121)	(135)	(267)
Net change in short-term debt		923	(13)	(154)
Acquisitions of treasury shares		(361)	(12)	(9)
Disposals of treasury shares		0	3	0
Net cash provided by/(used in) financing activities excluding the exchanged/held-for-exchange Animal Health business		(5,402)	(3,209)	(4,193)
Impact of exchange rates on cash and cash equivalents		(57)	12	9
Net change in cash and cash equivalents		6,542	(183)	2,502
Cash and cash equivalents, beginning of period		9,427	6,925	6,925
Cash and cash equivalents, end of period		15,969	6,742	9,427
Regeneron
Condensed Cash Flow Statements, Captions [Line Items]
Gain on Regeneron investment arising from transaction of May 29, 2020, net of tax		(6,870)	0	0
Proceeds from sale of Regeneron shares on May 29, 2020, net of transaction-related costs	[7]	€ 10,512	€ 0	€ 0

[1]	See Note C.2. to the financial statements for the year ended December 31, 2019
[2]	Includes non-current financial assets.
[3]	This line item includes contributions paid to pension funds (see Note B.12.).
[4]	Of which: ▪ Income tax paid (383) (724) (1,695) ▪ Interest paid (174) (202) (379) ▪ Interest received 29 56 92 ▪ Dividends received from non-consolidated entities — 1 —
[5]	This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations.
[6]	This line item includes proceeds from disposals of investments in consolidated entities and of other non-current financial assets. For the six months ended June 30, 2019 and the year ended December 31, 2019 it includes the divestment of Sanofi’s entire equity interests in Alnylam for €706 million and MyoKardia for €118 million. Net after-tax proceeds from disposals in the six months ended June 30, 2020 mainly relate to (i) the sale of operations relating to the Seprafilm product to Baxter for €313 million; (ii) the divestment of some established prescription products for €105 million; and (iii) contingent consideration of €167 million relating to a past divestment.
[7]	The amount recognized as of June 30, 2020 does not include the effects of the tax arising on the transaction, which will be paid in the second half of the year and is estimated at approximately €400 million.

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - EUR (€) € in Millions		6 Months Ended			12 Months Ended
		Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Condensed Cash Flow Statements, Captions [Line Items]
Income tax paid			€ (383)	€ (724)	€ (1,695)
Interest paid			(174)	(202)	(379)
Interest received			29	56	92
Dividends received from non-consolidated entities			0	1	0
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax	[1]		709	€ 867	1,224
Seprafilm
Condensed Cash Flow Statements, Captions [Line Items]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax			313
Pharmaceuticals
Condensed Cash Flow Statements, Captions [Line Items]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax			105
Other disposals of assets [member] \| Regeneron
Condensed Cash Flow Statements, Captions [Line Items]
Income taxes paid (refund), classified as investing activities		€ 400
Contingent consideration relating to divestments [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax			€ 167
Alnylam Pharmaceuticals, Inc \| Securities quoted in an active market
Condensed Cash Flow Statements, Captions [Line Items]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax					706
MyoKardia, Inc \| Securities quoted in an active market
Condensed Cash Flow Statements, Captions [Line Items]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax					€ 118

[1]	This line item includes proceeds from disposals of investments in consolidated entities and of other non-current financial assets. For the six months ended June 30, 2019 and the year ended December 31, 2019 it includes the divestment of Sanofi’s entire equity interests in Alnylam for €706 million and MyoKardia for €118 million. Net after-tax proceeds from disposals in the six months ended June 30, 2020 mainly relate to (i) the sale of operations relating to the Seprafilm product to Baxter for €313 million; (ii) the divestment of some established prescription products for €105 million; and (iii) contingent consideration of €167 million relating to a past divestment.

Introduction

Introduction	6 Months Ended
Introduction	Jun. 30, 2020
General Information About Financial Statements [Abstract]
Introduction	Sanofi, together with its subsidiaries (collectively “Sanofi” or “the Company”), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. Sanofi is listed in Paris (Euronext: SAN) and New York (Nasdaq: SNY). The condensed consolidated financial statements for the six months ended June 30, 2020 were reviewed by the Sanofi Board of Directors at the Board meeting on July 28, 2020.

Basis of Preparation of the Hal

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies	6 Months Ended
	Jun. 30, 2020
Corporate Information And Statement Of IFRS Compliance [Abstract]
Basis of Preparation of the Half-Year Financial Statements and Accounting Policies	A/ BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL STATEMENTS AND ACCOUNTING POLICIESA.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS) The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2019. The accounting policies used in the preparation of the consolidated financial statements as of June 30, 2020 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2020 are available via the following web link: https://www.efrag.org/Endorsement The accounting policies applied effective January 1, 2020 are identical to those presented in the consolidated financial statements for the year ended December 31, 2019. During 2018, the IASB published a number of amendments that are mandatorily applicable from January 1, 2020 onwards. These include “Definition of a Business” (an amendment to IFRS 3), issued October 22, 2018, which applies prospectively to business combinations completed on or after January 1, 2020. Applying this amendment did not have a material impact on the condensed consolidated half-year financial statements for the six months ended June 30, 2020. As a reminder, Sanofi early adopted the amendment to IFRS 9 relating to interest rate benchmark reform in its consolidated financial statements for the year ended December 31, 2019. A.2. USE OF ESTIMATES The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include: • amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions; • impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method; • the valuation of goodwill and the valuation and useful life of acquired intangible assets; • the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable; • the measurement of equity investments in unquoted entities; • the measurement of financial assets at amortized cost; • the amount of post-employment benefit obligations; • the amount of provisions for restructuring, litigation, tax risks (other than those related to income taxes) and environmental risks; and • the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences. Actual results could differ from these estimates. For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates. A.3. SEASONAL TRENDS Sanofi’s activities are not subject to significant seasonal fluctuations. A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES In 2020, Sanofi is continuing to account for subsidiaries in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. In 2018, following a change to the foreign exchange system, the “DICOM” rate was replaced by the “PETRO” rate (with a floating US dollar/bolivar parity) and the strong bolivar (“VEF”) by a new currency known as the sovereign bolivar (“VES”), reflecting a 1-for-100,000 devaluation. Consequently, the contribution of the Venezuelan subsidiaries to the Sanofi consolidated financial statements is immaterial. In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy, and applied IAS 29. The impact on the consolidated income statement of adjustments required for the application of IAS 29 to Argentinean hyperinflation as of June 30, 2020 is an expense of €16 million; the impact on balance sheet line items as of that date is immaterial. A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: • Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); • Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; • Level 3: valuation techniques in which not all important inputs are derived from observable market data. The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Market data Valuation model Exchange rate Interest rate Volatilities B.6. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Amortized cost/ Peer comparison (primarily) If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used. B.6. Financial assets at fair value (contingent consideration receivable) Fair value 3 Revenue-based approach Under IFRS 9, contingent consideration receivable on a divestment is a financial asset. The fair value of such assets is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2019. B.6. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. B.6. Financial assets recognized under the fair value option (a) Fair value 1 Market value Quoted market price N/A B.10. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market> 1 year: Mid Zero Coupon N/A B.10. Interest rate swaps Fair value 2 Revenue-based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.9. Investments in mutual funds Fair value 1 Market value Net asset value N/A B.9. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. B.9. Debt Amortized cost (b) N/A N/A In the case of debt with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For debt with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). B.9. Lease liabilities Amortized cost N/A N/A Future lease payments are discounted using the incremental borrowing rate B.11. Liabilities related to business combinations and to non-controlling interests (CVRs) Fair value 1 Market value Quoted market price N/A B.11. Liabilities related to business combinations and to non-controlling interests (other than CVRs) Fair value (c) 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) These assets are held to fund a deferred compensation plan offered to certain employees. (b) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s). (c) For business combinations completed prior to application of the revised IFRS 3, contingent consideration is recognized when payment becomes probable. See Note B.3.1. to the consolidated financial statements for the year ended December 31, 2019. A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM JUNE 2020 OR LATER On May 28, 2020, the IASB issued “Covid-19-Related Rent Concessions”, an amendment to IFRS 16. The amendment, which is applicable from June 1, , 2020 (subject to endorsement by the European Union), allows lessees not to account for rent concessions as lease modifications if they are a direct consequence of Covid-19 and meet certain conditions. Sanofi does not expect a material impact from the application of this amendment. On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1. On May 14, 2020, the IASB issued “Reference to the Conceptual Framework”, an amendment to IFRS 3; Proceeds before Intended Use”, an amendment to IAS 16; “Onerous Contracts – Cost of Fulfilling a Contract”, an amendment to IAS 37; and “Annual Improvements to IFRS standards 2018-2020”. Sanofi does not expect a material impact from those amendments, which are applicable at the earliest from January 1, 2022 (subject to endorsement by the European Union). Sanofi will not early adopt those amendments. A.7. COVID-19 PANDEMIC Covid-19, confirmed as a pandemic by the World Health Organisation on March 11, 2020, has led to a global health crisis. Sanofi has assessed the impact of the uncertainties created by the Covid-19 pandemic. As of June 30, 2020, those uncertainties have not appreciably called into question the estimates and assumptions made by management (see Note A.2.). Sanofi will continue to reassess those estimates and assumptions as the situation evolves. Effect of the Covid-19 pandemic on the valuation of goodwill and intangible assets In accordance with IAS 36 (Impairment of Assets), Sanofi conducts impairment tests on goodwill allocated to each of its Cash Generating Units and on other intangible assets not yet available for use (such as capitalized in process research and development) on an annual basis, regardless of whether there is an indication that they might have become impaired. The most recent impairment tests were conducted as of December 31, 2019 (see Note D.5. to the consolidated financial statements for the year ended December 31, 2019). In light of the Covid-19 pandemic, in preparing the 2020 half-year consolidated financial statements Sanofi assessed the following indicators, and found no indication that the assets in question might have become impaired as a result of the pandemic: – quoted market price of shares in Sanofi and peers in the healthcare sector; – trends in interest rates and risk premiums; – trends in sales and earnings for each CGU during the first half of 2020; – 2020 full-year sales and operating profit forecasts for each CGU; – progress on research and development programs; – supply chain and activity levels at Sanofi’s industrial facilities; and – changes to long-term business plans. In addition, the goodwill impairment tests conducted in 2019 showed that for each CGU, the recoverable amount was substantially higher than the carrying amount (see Note D.5. to the consolidated financial statements for the year ended December 31, 2019). Consequently, in accordance with IAS 36, the Cash Generating Units to which goodwill is allocated have not been tested for impairment. Finally, Sanofi has conducted impairment tests related to the specific circumstances of some intangible assets with no direct link to the Covid-19 pandemic; the results of those tests are described in Note B.4. Effect of the Covid-19 pandemic on accounts receivable As of June 30, 2020, Sanofi analysed indicators that its accounts receivable might have become impaired, such as the ageing of gross receivables and the amount of doubtful receivables (see Note B.7). Nothing was identified that would indicate a material increase in expected credit risk, especially as regards Sanofi’s principal customers (see Note B.20.4). Effect of the Covid-19 pandemic on the liquidity position The Covid-19 pandemic has not had a negative impact on Sanofi’s liquidity position. Effect of the Covid-19 pandemic on the presentation of the income statement The effects of the Covid-19 pandemic are presented in the relevant line items of the income statement, according to the function or nature of the income or expense.

Changes in the Scope of Consoli

Changes in the Scope of Consolidation Due to Acquisitions and Divestments	6 Months Ended
	Jun. 30, 2020
Business Combinations 1 [Abstract]
Changes in the Scope of Consolidation Due to Acquisitions and Divestments	B.1. CHANGES IN THE SCOPE OF CONSOLIDATION DUE TO ACQUISITIONS AND DIVESTMENTS Acquisition of Synthorx On December 9, 2019, Sanofi and Synthorx Inc. (“Synthorx”), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi was to acquire all of the outstanding shares of Synthorx for $68 per share in cash, representing an aggregate equity value of approximately $2.5 billion (on a fully diluted basis). The transaction was unanimously approved by both the Sanofi and Synthorx Boards of Directors. On December 23, 2019, Sanofi launched a public tender offer to acquire all of the outstanding shares of Synthorx for $68 per share in cash, without interest and net of any applicable withholding taxes. The acquisition of Synthorx was completed on January 23, 2020, with Sanofi holding all of the shares following the expiration of the tender offer. The provisional purchase price allocation, as presented in the table below, resulted in the recognition of goodwill of €901 million: (€ million) Fair value at acquisition date Intangible assets other than goodwill 1,549 Other current and non-current assets and liabilities 41 Net deferred tax position (245) Net assets of Synthorx 1,345 Goodwill 901 Purchase price 2,246 Intangible assets other than goodwill mainly comprise THOR-707, a molecule currently in Phase I clinical trials that stimulates T lymphocytes, and as such has potential as a cancer immunotherapy. Goodwill represents (i) the pipeline of future products in pre-clinical research and development; (ii) the capacity to draw on a specialized structure to refresh the existing product portfolio; (iii) the competencies of Synthorx staff; (iv) benefits derived from the creation of new growth platforms; and (v) expected future synergies and other benefits from the combination of Synthorx and Sanofi. The goodwill generated on this acquisition did not give rise to any deduction for income tax purposes. Synthorx has no commercial operations, and has made a negative contribution of €70 million to Sanofi’s consolidated net income since the acquisition date. Acquisition-related costs recognized in profit or loss for the year ended December 31, 2019 were recorded mainly within the line item Other operating expenses , and were of an immaterial amount. The impact of this acquisition, reflected in the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method within the consolidated statement of cash flows, was a cash outflow of €2,246 million. Transaction related to the equity-accounted investment in Regeneron From the beginning of April 2014, Sanofi accounted for its investment in Regeneron using the equity method. As from that date, in accordance with the Investor Agreement as amended in January 2014, Sanofi had the right to designate a member of the Regeneron Board of Directors. On May 29, 2020, Sanofi closed the transaction announced on May 25, 2020 involving the sale of its equity investment in Regeneron (with the exception of 400,000 shares), through (i) a registered public offering in the United States and internationally and (ii) a share repurchase by Regeneron. Sanofi sold 13 million shares of Regeneron common stock through the public offering at a price of $515 per share, raising a total amount of $6.7 billion; and Regeneron repurchased 9.8 million of its own shares of common stock directly from Sanofi for $5 billion, at the offer price less a subscription discount ($509.85 per share). The total sale proceeds (before transaction-related costs) amounted to €10,575 million. At the same time, Sanofi as a result of this transaction lost the right to designate a member of the Regeneron Board of Directors under the amended Investor Agreement. Finally, as of May 29, 2020 Sanofi retained ownership of 400,000 Regeneron shares in order to continue to partially fund its commitments to invest in the development programs for cemiplimab (REGN2810) and dupilumab, in line with the 2018 Letter Agreement under which Sanofi is permitted to sell up to 1.4 million shares through the end of 2020. As of June 30, 2020, Sanofi had sold 779,320 Regeneron shares under that agreement. The number of retained shares held by Sanofi under that agreement is 279,766 as of the end of June (see note C.1. to the consolidated financial statements as of December 31, 2019). Sanofi’s equity investment in Regeneron was accounted for by the equity method until May 29, 2020. As of that date, the carrying amount of the investment was €3,668 million; that amount was reversed out on closing of the transaction. Before tax effects, the gain on the divestment amounted to €7,382 million, including (i) a gain of €318 million arising on the currency translation reserve associated with Regeneron, which was taken to profit or loss in accordance with IAS 21; (ii) the deduction of transaction-related costs of €64 million; and (iii) a gain of €157 million on the remeasurement of the 400,000 retained shares at their quoted market price as of May 29, 2020 ($612.81). In accordance with IFRS 9 (Financial Instruments), the retained shares were classified in the “Equity instruments at fair value through other comprehensive income” category on the transaction date, at a value of €221 million ( See note B.6.). The tax charge arising on the transaction was €512 million. Given the material impact of this transaction, and to facilitate users’ understanding of the financial statements, the pre-tax gain on this transaction is presented as a separate line item in the consolidated income statement, Gain on Regeneron investment arising from the transaction of May 29, 2020 . The net cash inflow from the transaction was €10,512 million, which (for the reason cited above) is presented as a separate line item in the consolidated statement of cash flows, Net proceeds from sale of Regeneron shares on May 29, 2020.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
Property, Plant and Equipment	Jun. 30, 2020
Property, plant and equipment [abstract]
Property, Plant and Equipment	B.2. PROPERTY, PLANT AND EQUIPMENT The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2020: (€ million) June 30, 2020 December 31, 2019 Acquisitions 389 1,261 Pharmaceuticals 234 846 Industrial facilities 196 682 Research sites 37 87 Other 1 77 Vaccines 128 405 Consumer Healthcare 27 10 Capitalized interest 6 14

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
Goodwill and Other Intangible Assets	Jun. 30, 2020
Intangible Assets [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	B.3. GOODWILL AND OTHER INTANGIBLE ASSETS Movements in other intangible assets during the first half of 2020 were as follows: (€ million) Acquired R&D Products, trademarks and other rights Software Total other intangible assets Gross value at January 1, 2020 5,730 63,953 1,698 71,381 Changes in scope of consolidation (a) 1,417 132 — 1,549 Acquisitions and other increases 115 38 65 218 Disposals and other decreases (17) (106) (12) (135) Currency translation differences (28) (118) (11) (157) Transfers (b) (52) 52 (2) (2) Gross value at June 30, 2020 7,165 63,951 1,738 72,854 Accumulated amortization and impairment at January 1, 2020 (3,396) (50,314) (1,099) (54,809) Amortization expense — (895) (62) (957) Impairment losses, net of reversals (c) (321) (2) — (323) Disposals and other decreases 17 105 13 135 Currency translation differences 2 107 9 118 Transfers 18 (15) — 3 Accumulated amortization and impairment at June 30, 2020 (3,680) (51,014) (1,139) (55,833) Carrying amount at January 1, 2020 2,334 13,639 599 16,572 Carrying amount at June 30, 2020 3,485 12,937 599 17,021 (a) See Note B.1. (b) This line mainly represents Sarclisa ® (Oncology) and MenQuadfi TM (Vaccines), which came into commercial use during the period. (c) See Note B.4. Acquisitions of other intangible assets (excluding software) in the first half of 2020 totaled €153 million. The main items were upfront and milestone payments within the Specialty Care franchise. “Products, trademarks and other rights” mainly comprises: • marketed products, with a carrying amount of €12.5 billion as of June 30, 2020 (versus €13.3 billion as of December 31, 2019) and a weighted average amortization period of approximately 10 years; • trademarks, with a carrying amount of €0.1 billion as of June 30, 2020 (versus €0.1 billion as of December 31, 2019) and a weighted average amortization period of approximately 12 years. Goodwill amounted to €45,254 million as of June 30, 2020, versus €44,519 million as of December 31, 2019. Movements during the first half of 2020 were mainly due to the goodwill of €901 million arising on the Synthorx acquisition (see Note B.1.) and the effects of foreign currency translation differences on goodwill recognised in currencies other than Sanofi’s reporting currency.

Impairment of Intangible Assets

Impairment of Intangible Assets	6 Months Ended
Impairment of Intangible Assets	Jun. 30, 2020
Impairment Of Assets [Abstract]
Impairment of Intangible Assets	B.4. IMPAIRMENT OF INTANGIBLE ASSETS The results of impairment tests on other intangible assets led to the recognition of a net impairment loss of €323 million in the first half of 2020. Most of the impairment losses recognized during the period related to research and development projects in the Pharmaceuticals segment.

Investments Accounted for Using

Investments Accounted for Using the Equity Method	6 Months Ended
Investments Accounted for Using the Equity Method	Jun. 30, 2020
Interests In Other Entities [Abstract]
Investments Accounted for Using the Equity Method	B.5. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2019), and comprise: (€ million) % interest June 30, 2020 December 31, 2019 Regeneron Pharmaceuticals, Inc. (a) — 3,342 Infraserv GmbH & Co. Höchst KG (b) 31.2 62 70 Entities and companies managed by Bristol-Myers Squibb (c) 100.0 — 37 Other investments — 134 142 Total 196 3,591 (a) Following the transaction of May 29, 2020 as described in Note B.1. above, which resulted in the divestment of 22.8 million Regeneron shares, Sanofi no longer exercises significant influence over Regeneron. As of that date, Sanofi retained 0.4 million Regeneron shares, classified in the “Equity instruments at fair value through other comprehensive income” category (see Note B.6.) (b) Joint venture. (c) On February 29, 2020, Sanofi acquired from Bristol-Myers Squibb the remaining 50.1% equity interest not yet held by Sanofi in the three partnerships that organize the commercialization of Plavix ® in the United States and Puerto Rico, for a total consideration of $12 million. This acquisition was accounted for in accordance with IFRS 3 (Business Combinations). The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below: (€ million) June 30, 2020 June 30, 2019 December 31, 2019 Sales (a) 52 16 24 Royalties and other income (a) 65 153 270 Accounts receivable and other receivables 7 160 151 Purchases and other expenses (including research expenses) (a) 605 608 1,334 Accounts payable and other payables 5 373 342 (a) For the six months ended June 30, 2020, these amounts include transactions between Sanofi and Regeneron for the period from January 1 through May 29, 2020. The table above does not include the repurchase by Regeneron of its own shares from Sanofi (see Note B.1.).

Other Non-Current Assets

Other Non-Current Assets	6 Months Ended
Other Non-Current Assets	Jun. 30, 2020
Subclassifications of assets, liabilities and equities [abstract]
Other Non-Current Assets	B.6. OTHER NON-CURRENT ASSETS Other non-current assets comprise: (€ million) June 30, 2020 December 31, 2019 Equity instruments at fair value through other comprehensive income 872 380 Debt instruments at fair value through other comprehensive income 439 403 Other financial assets at fair value through profit or loss 812 892 Pre-funded pension obligations 156 155 Long-term prepaid expenses 103 115 Long-term loans and advances and other non-current receivables 616 685 Derivative financial instruments 33 37 Total 3,031 2,667 Equity instruments at fair value through other comprehensive income amounted to €872 million as of June 30, 2020. The main changes in this line item during the period are described below: • As mentioned in Note B.1., following Sanofi's announcement on May 29, 2020 of the divestment of 22.8 million shares of Regeneron common stock, Sanofi ceased to exercise significant influence over Regeneron and hence ceased to account for this investment by the equity method (see Note B.5.). In accordance with IFRS 9 (Financial Instruments), the 400,000 retained shares were classified effective May 29, 2020 within Equity instruments at fair value through other comprehensive income , at a value of €221 million. As of June 30, 2020, Sanofi held 279,766 Regeneron shares, with a carrying amount in the balance sheet of € 152 million. • Sanofi owns equity interests in quoted biotechnology companies. Movements in the quoted market prices of the shares held in those companies generated a net gain of €360 million, recognised in Equity instruments at fair value through other comprehensive income

Accounts Receivable

Accounts Receivable	6 Months Ended
Accounts Receivable	Jun. 30, 2020
Subclassifications of assets, liabilities and equities [abstract]
Accounts Receivable	B.7. ACCOUNTS RECEIVABLE Accounts receivable break down as follows: (€ million) June 30, 2020 December 31, 2019 Gross value 7,379 8,090 Allowances (176) (153) Carrying amount 7,203 7,937 The impact of allowances against accounts receivable in the first half of 2020 was a net expense of €40 million (versus a net gain of €2 million for the first half of 2019). The table below shows the ageing profile of overdue accounts receivable, based on gross value: (€ million) Overdue accounts gross value Overdue by <1 month Overdue by 1-3 months Overdue by 3-6 months Overdue by 6-12 months Overdue by > 12 months June 30, 2020 633 210 208 81 29 105 December 31, 2019 642 269 171 61 36 105 Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.7. to the consolidated financial statements for the year ended December 31, 2019 and hence were derecognized was €322 million as of June 30, 2020 (versus €214 million as of December 31, 2019). The residual guarantees relating to those transfers were immaterial as of June 30, 2020.

Consolidated Shareholders' Equi

Consolidated Shareholders' Equity	6 Months Ended
Consolidated Shareholders' Equity	Jun. 30, 2020
Share Capital, Reserves And Other Equity Interest [Abstract]
Consolidated Shareholders' Equity	B.8. CONSOLIDATED SHAREHOLDERS’ EQUITY B.8.1. SHARE CAPITAL As of June 30, 2020, the share capital was €2,512,384,148 and consisted of 1,256,192,074 shares (the total number of shares outstanding) with a par value of €2. Treasury shares held by Sanofi are as follows: Number of shares % of share capital June 30, 2020 2.59 0.207 % December 31, 2019 0.02 0.002 % June 30, 2019 0.02 0.002 % January 1, 2019 1.94 0.156 % A total of 679,707 shares were issued in the first half of 2020 as a result of the exercise of Sanofi stock subscription options. A total of 3,073,755 shares vested under Sanofi restricted share plans during the first half of 2020, either by issuance of new shares or by vesting of existing restricted shares. B.8.2. REPURCHASE OF SANOFI SHARES On April 28, 2020, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Sanofi did not use that authorization during the first half of 2020. On April 30, 2019, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Under that program (and that program alone), Sanofi repurchased 3,982,939 of its own shares during the first half of 2020 for a total amount of €361 million. B.8.3. REDUCTIONS IN SHARE CAPITAL No decision to cancel treasury shares was made by the Sanofi Board of Directors during the first half of 2020. B.8.4. RESTRICTED SHARE PLANS Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2019. The principal features of the plans awarded in 2020 are set forth below: 2020 Type of plan Performance share plan Date of Board meeting approving the plan April 28, 2020 Total number of shares subject to a 3-year service period 3,340,501 Fair value per share awarded (a) 82.36 Fair value of plan at the date of grant (€ million) 275 (a) Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period. The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below: June 30, 2020 June 30, 2019 Total expense for restricted share plans (€ million) 113 128 Number of shares not yet fully vested 10,900,815 11,251,318 Under 2020 plans 3,340,501 — Under 2019 plans 3,545,507 3,797,582 Under 2018 plans 4,014,807 4,252,339 Under 2017 plans — 3,201,397 B.8.5. CAPITAL INCREASES On February 5, 2020, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of €70.67 per share. The subscription period was open from June 8 through June 26, 2020. Sanofi employees subscribed for a total of 2,467,101 shares, and this capital increase was supplemented by the issuance of a further 123,615 shares for the employer’s contribution. The total expense recognized for this capital increase in the first half of 2020 was €52 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees. There were no capital increases reserved for employees in the first half of 2019. B.8.6. STOCK SUBSCRIPTION OPTION PLANS No stock subscription option plans were awarded in the first half of 2020. The table below shows, for each of the periods reported, the expense recognized through equity for stock option plans: (€ million) June 30, 2020 June 30, 2019 Expense recognized through equity — 3 The table below provides summary information about options outstanding and exercisable as of June 30, 2020: Range of exercise prices per share Outstanding Exercisable Number of options Weighted average residual life (years) Weighted average exercise price per share (€) Number of options Weighted average exercise price per share (€) From €50.00 to €60.00 per share 277,506 1.32 54.28 277,506 54.28 From €60.00 to €70.00 per share 220,000 7.85 65.84 — — From €70.00 to €80.00 per share 1,591,528 4.60 74.11 1,371,528 73.69 From €80.00 to €90.00 per share 712,804 5.85 89.19 384,964 89.38 Total 2,801,838 2,033,998 B.8.7. NUMBER OF SHARES USED TO COMPUTE DILUTED EARNINGS PER SHARE Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares. (million) June 30, 2020 June 30, 2019 December 31, 2019 Average number of shares outstanding 1,251.7 1,247.2 1,249.9 Adjustment for stock options with dilutive effect 0.4 1.0 0.8 Adjustment for restricted shares 6.1 6.5 6.4 Average number of shares used to compute diluted earnings per share 1,258.2 1,254.7 1,257.1 As of June 30, 2020, 0.7 million stock options were not taken into account in computing diluted earnings per share because they had no dilutive effect, compared with 0.8 million as of December 31, 2019 and 1.1 million as of June 30, 2019. B.8.8. OTHER COMPREHENSIVE INCOME Movements within other comprehensive income are shown below: (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Actuarial gains/(losses): ▪ Actuarial gains/(losses) excluding investments accounted for using the equity method (146) (535) (377) ▪ Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes — — (5) ▪ Tax effects (19) 155 161 Equity instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) (a) 312 19 26 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) (13) 15 80 ▪ Tax effects (70) (38) (48) Items not subsequently reclassifiable to profit or loss 64 (384) (163) Debt instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) (b) 4 28 28 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects (1) (5) (5) Cash flow hedges: ▪ Change in fair value (excluding investments accounted for using the equity method) (c) 29 (15) (13) ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects (9) 4 4 Change in currency translation differences: ▪ Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method) (c) (590) 462 850 ▪ Currency translation differences (investments accounted for using the equity method) 24 23 64 ▪ Currency translation differences related to the investment in Regeneron and reclassified to profit or loss (d) (318) — — ▪ Hedges of net investments in foreign operations (60) (75) (163) ▪ Tax effects 19 18 48 Items subsequently reclassifiable to profit or loss (902) 440 813 (a) In 2020, includes a negative movement of €53 million for a change in the fair value of the equity instrument derivatives (collars) on shares in Dexcom, Inc contracted by Sanofi in 2019 and designated as a fair value hedge. (b) There were no reclassifications to profit or loss in the first half of 2020 or in 2019. (c) Includes reclassifications to profit or loss: €1 million in the first half of 2020 and €27 million in 2019 (of which €20 million was reclassified in the first half of 2019). (d) Amount of cumulative currency translation differences associated with the equity investment in Regeneron, reclassified to profit or loss in accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates).

Debt, Cash and Cash Equivalents

Debt, Cash and Cash Equivalents	6 Months Ended
Debt, Cash and Cash Equivalents	Jun. 30, 2020
Financial Instruments [Abstract]
Debt, Cash and Cash Equivalents	B.9. DEBT, CASH AND CASH EQUIVALENTS Changes in financial position during the period were as follows: (€ million) June 30, 2020 December 31, 2019 Long-term debt 20,404 20,131 Short-term debt and current portion of long-term debt 3,329 4,554 Interest rate and currency derivatives used to manage debt (173) (117) Total debt 23,560 24,568 Cash and cash equivalents (15,969) (9,427) Interest rate and currency derivatives used to manage cash and cash equivalents 89 (34) Net debt (a) 7,680 15,107 (a) Net debt does not include lease liabilities, which amounted to €1,195 million as of June 30, 2020 and €1,248 million as of December 31, 2019. “Net debt” is a financial indicator used by management and investors to measure Sanofi’s overall net indebtedness. B.9.1. NET DEBT AT VALUE ON REDEMPTION A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2020 is shown below: (€ million) Value on redemption Carrying amount at June 30, 2020 Amortized cost Adjustment to debt measured at fair value June 30, 2020 December 31, 2019 Long-term debt 20,404 77 (53) 20,428 20,180 Short-term debt and current portion of long-term debt 3,329 2 (2) 3,329 4,553 Interest rate and currency derivatives used to manage debt (173) — 29 (144) (86) Total debt 23,560 79 (26) 23,613 24,647 Cash and cash equivalents (15,969) — — (15,969) (9,427) Interest rate and currency derivatives used to manage cash and cash equivalents 89 — — 89 (34) Net debt (a) 7,680 79 (26) 7,733 15,186 (a) Net debt does not include lease liabilities, which amounted to €1,195 million as of June 30, 2020 and €1,248 million as of December 31, 2019. The table below shows an analysis of net debt by type, at value on redemption: (€ million) June 30, 2020 December 31, 2019 non-current current Total non-current current Total Bond issues 20,340 1,890 22,230 20,128 4,079 24,207 Other bank borrowings 75 1,131 1,206 40 156 196 Other borrowings 13 1 14 13 12 25 Bank credit balances — 307 307 — 305 305 Interest rate and currency derivatives used to manage debt — (144) (144) — (86) (86) Total debt 20,428 3,185 23,613 20,181 4,466 24,647 Cash and cash equivalents — (15,969) (15,969) — (9,427) (9,427) Interest rate and currency derivatives used to manage cash and cash equivalents — 89 89 (6) (28) (34) Net debt 20,428 (12,695) 7,733 20,175 (4,989) 15,186 Principal financing and debt reduction transactions during the period In March 2020, Sanofi carried out a €1.5 billion bond issue in two tranches: • €750 million of fixed-rate bonds maturing April 2025, bearing interest at an annual rate of 1.000%; and • €750 million of fixed-rate bonds maturing April 2030, bearing interest at an annual rate of 1.500%. In April 2020, Sanofi carried out a €500 million tap issue on those two bond tranches: • €250 million of fixed-rate bonds, which increased to €1 billion the principal of the tranche maturing April 2025 and bearing interest at an annual rate of 1.000%; and • €250 million of fixed-rate bonds, which increased to €1 billion the principal of the tranche maturing April 2030 and bearing interest at an annual rate of 1.500%. Five bond issues were redeemed in the first half of 2020: • a September 2016 fixed-rate bond issue of €1 billion, which matured on January 13, 2020; • a March 2018 floating-rate bond issue of €1 billion, which matured on March 21, 2020; • a March 2018 fixed-rate bond issue of €500 million, which matured on March 21, 2020; • a September 2013 fixed-rate bond issue of €1 billion maturing September 2020, redeemed early on June 4, 2020; and • a June 2010 fixed-rate bond issue of $500 million carried out by Genzyme Corp, which matured on June 15, 2020. Sanofi had the following arrangements in place as of June 30, 2020 to manage its liquidity in connection with current operations: • a syndicated credit facility of €4 billion, drawable in euros and in US dollars, due to expire on December 17, 2020 following the exercise of a second extension option in November 2015; and • a syndicated credit facility of €4 billion, drawable in euros and in US dollars, due to expire on December 3, 2021 following the exercise of a second extension option in November 2016. Sanofi has no further extension options for those facilities. As of June 30, 2020, there were no drawdowns under either facility. Sanofi also has a €6 billion Negotiable European Commercial Paper program in France and a $10 billion Commercial Paper program in the United States. During the first half of 2020 only the US program was used, with an average drawdown of $2.6 billion. The financing in place as of June 30, 2020 at the level of the holding company (which manages most of Sanofi’s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating. B.9.2. MARKET VALUE OF NET DEBT The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows: (€ million) June 30, 2020 December 31, 2019 Market value 9,126 16,370 Value on redemption 7,733 15,186

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
Derivative Financial Instruments	Jun. 30, 2020
Financial Instruments [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS	B.10. DERIVATIVE FINANCIAL INSTRUMENTS B.10.1 CURRENCY DERIVATIVES USED TO MANAGE OPERATING RISK EXPOSURES The table below shows operating currency hedging instruments in place as of June 30, 2020. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2020 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 3,251 15 – – – 3,251 15 of which US dollar 1,070 7 – – – 1,070 7 of which Chinese yuan renminbi 493 1 – – – 493 1 of which Singapore dollar 203 — – – – 203 — of which Japanese yen 182 4 – – – 182 4 of which Saudi riyal 158 — – – – 158 — Forward currency purchases 1,552 (8) – – – 1,552 (8) of which US dollar 537 (1) – – – 537 (1) of which Singapore dollar 487 (3) – – – 487 (3) of which Canadian dollar 68 — – – – 68 — of which Korean won 46 — – – – 46 — of which Japanese yen 41 — – – – 41 — Total 4,803 7 – – – 4,803 7 The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June 30, 2020 and recognized in the balance sheet at that date. Gains and losses on hedging in struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of 2020. B.10.2. CURRENCY AND INTEREST RATE DERIVATIVES USED TO MANAGE FINANCIAL EXPOSURE The cash pooling arrangements for foreign subsidiaries outside the euro zone, and some of Sanofi’s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e. the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower). That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi’s debt once those instruments are taken into account. The table below shows financial currency hedging instruments in place as of June 30, 2020. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2020 (€ million) Notional amount Fair value Maximum expiry date Forward currency sales 5,213 88 of which US dollar 3,660 (a) 87 2020 of which Japanese yen 320 2 2020 of which Australian dollar 225 (1) 2020 Forward currency purchases 10,824 (39) of which US dollar 7,056 (b) (19) 2021 of which Singapore dollar 2,443 (c) (11) 2021 of which Japanese yen 384 (4) 2020 Total 16,037 49 (a) Includes forward sales with a notional amount of $3,615 million expiring in 2020, designated as a hedge of Sanofi’s net investment in Bioverativ. As of June 30, 2020, the fair value of these forward contracts represented an asset of €88 million; the opposite entry was recognized in Other comprehensive incom e, with the impact on financial income and expense being immaterial. (b) Includes forward purchases with a notional amount of $4,000 million expiring in 2020, designated as a fair value hedge of USD bond issues against fluctuations in the EUR/USD spot rate. As of June 30, 2020, the fair value of these contracts represented an asset of €87 million, with €21 million of that amount credited to Other comprehensive income to recognise the hedging cost. (c) Includes forward purchases with a notional amount of SGD 2,000 million expiring in 2020 and 2021, designated as fair value hedges of an equivalent portion of an intra-group loan against fluctuations in the EUR/SGD spot rate. As of June 30, 2020, the fair value of these contracts represented a liability of €2 million, with €12 million credited to Other comprehensive income to recognise the hedging cost. To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt. The table below shows instruments of this type in place as of June 30, 2020: Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2020 2021 2022 2023 2024 Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized Eonia / receive 0.06% — — 2,000 — — 2,000 30 2,000 30 — — — pay -0.57% / receive capitalized Eonia — — 600 — — 600 3 — — 600 3 — pay 1.81% / receive 3-month USD Libor 445 — — — — 445 (4) — — 445 (4) (1) pay 3-month USD Libor / receive 2.22% 445 — — — — 445 5 445 5 — — — receive capitalized Eonia / pay 1.48% (a) — — 42 57 — 99 (5) 99 (5) — — — Total 890 — 2,642 57 — 3,589 29 2,544 30 1,045 (1) (1) (a) These interest rate swaps hedge fixed-rate bonds with a nominal of €99 million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within “Loans, advances and other long-term receivables”. B.10.3. EQUITY DERIVATIVES During 2019, Sanofi contracted derivative instruments (collars) on 593,712 shares of Dexcom, Inc. The collars were designated as fair value hedges of the Dexcom shares, and had a negative fair value as of June 30, 2020 of €57 million, recognized in full in Other comprehensive income .

Liabilities Related to Business

Liabilities Related to Business Combinations and to Non-Controlling Interest	6 Months Ended
	Jun. 30, 2020
Business Combinations 1 [Abstract]
Liabilities Related to Business Combinations and to Non-Controlling Interest	B.11. LIABILITIES RELATED TO BUSINESS COMBINATIONS AND TO NON-CONTROLLING INTERESTS For a description of the nature of the liabilities reported in the line item Liabilities related to business combinations and to non-controlling interests , refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2019. The liabilities related to business combinations and to non-controlling interests shown in the table below are level 3 instruments under the IFRS 7 fair value hierarchy (see Note A.5.). Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2020 are shown below: (€ million) Bayer contingent consideration arising from the acquisition of Genzyme MSD contingent consideration (European Vaccines business) Other Total (a) Balance at January 1, 2020 156 385 259 800 Payments made (37) (78) (2) (117) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) 11 37 (72) (24) Other movements — — (2) (2) Currency translation differences 1 (4) 2 (1) Balance at June 30, 2020 131 340 185 656 Of which: • Current portion 243 • Non-current portion 413 (a) As of January 1, 2020, this comprised a non-current portion of €508 million and a current portion of €292 million. (b) Amounts reported within the income statement line item Fair value remeasurement of contingent consideration. As of June 30, 2020, Liabilities related to business combinations and to non-controlling interests mainly comprised: • The liability arising from the acquisition of True North Therapeutics by Bioverativ. The former shareholders of True North Therapeutics are entitled to milestone payments contingent on the attainment of development, registration and sales objectives; the fair value of the resulting liability was measured at €156 million as of June 30, 2020, versus €230 million as of December 31, 2019. That fair value is determined based on the contractual terms and on development and sales projections which have been weighted to reflect the probability of success, and discounted. If the discount rate were to fall by one percentage point, the fair value of the contingent consideration would increase by approximately 1%. • The Bayer contingent consideration liability arising from the acquisition of Genzyme in 2011. As of June 30, 2020, Bayer was still entitled to receive the following potential payments: – a percentage of sales of alemtuzumab up to a maximum of $1,250 million or over a maximum period of 10 years, whichever is achieved first; – milestone payments based on specified levels of worldwide sales of alemtuzumab beginning in 2021, unless Genzyme exercises its right to buy out those milestone payments by making a one-time payment not exceeding $900 million. The fair value of this liability was measured at €131 million as of June 30, 2020, versus €156 million as of December 31, 2019. The fair value of the Bayer liability is determined by applying the above contractual terms to sales projections which have been weighted to reflect the probability of success, and discounted. If the discount rate were to fall by one percentage point, the fair value of the Bayer liability would increase by approximately 2%. • The MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to €340 million as of June 30, 2020 versus €385 million as of December 31, 2019. The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted sales projections. If the discount rate were to fall by one percentage point, the fair value of the MSD contingent consideration would increase by approximately 3%.

Provisions and Other Liabilitie

Provisions and Other Liabilities	6 Months Ended
Provisions and Other Liabilities	Jun. 30, 2020
Subclassifications of assets, liabilities and equities [abstract]
PROVISIONS AND OTHER LIABILITIES	B.12. PROVISIONS AND OTHER LIABILITIES B.12.1. NON-CURRENT PROVISIONS AND OTHER NON-CURRENT LIABILITIES The line item Non-current provisions and other non-current liabilities breaks down as follows: (€ million) June 30, 2020 June 30, 2019 December 31, 2019 Non-current provisions 7,768 7,401 7,353 Other non-current liabilities 2,017 1,698 1,968 Total 9,785 9,099 9,321 B.12.1.1. PROVISIONS The table below shows movements in provisions: (€ million) Provisions for pensions & other post-employment benefits Provisions for other long-term benefits Restructuring provisions Other provisions Total Balance at January 1, 2020 3,827 855 600 2,071 7,353 Increases in provisions and other liabilities 144 60 531 (a) 149 884 Provisions utilized (47) (66) (2) (98) (213) Reversals of unutilized provisions (93) — (21) (78) (b) (192) Transfers — (1) (117) (c) (76) (194) Net interest related to employee benefits, and unwinding of discount 29 1 — 5 35 Currency translation differences (24) (2) (3) (22) (51) Actuarial gains and losses on defined-benefit plans 146 — — — 146 Balance at June 30, 2020 3,982 847 988 1,951 7,768 (a) Charges to restructuring provisions relate mainly to headcount adjustment plans in Europe. (b) Amounts charged during the first half of 2020 relate mainly to provisions for products, litigation and other liabilities (c) This movement includes transfers between current and non-current. Provisions for pensions and other post-employment benefits For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December 31, 2019, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December 31, 2019. The principal assumptions used (in particular, changes in discount and inflation rates and in the market value of plan assets) for the euro zone, the United States and the United Kingdom were reviewed as of June 30, 2020 to take into account changes during the first half of the year. Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax): (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Actuarial gains/(losses) on plan assets 308 655 926 Actuarial gains/(losses) on benefit obligations (454) (a) (1,190) (b) (1,301) (a) Includes the effects of (i) the change in the discount rate in the United Kingdom and the United States (-0.50%) and (ii) the change in the inflation rate in the United Kingdom (-0.05%) in the first half of 2020. (b) Includes the effects of changes in discount rates (in a range between -0.65% and -1.00%) and in the United Kingdom inflation rate (+0.05%) in the first half of 2019. B.12.1.2. OTHER NON-CURRENT LIABILITIES Other non-current liabilities comprise the following : (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Non-current liabilities related to income taxes (a) 1,712 1,452 1,666 Other non-current liabilities 305 246 302 Total 2,017 1,698 1,968 (a) Non-current liabilities related to income taxes include uncertainties over income tax treatments amounting to €1,064 million as of June 30, 2020, €812 million as of June 30, 2019, and €1,031 million as of December 31, 2019. B.12.2. CURRENT PROVISIONS AND OTHER CURRENT LIABILITIES The net change in Current provisions and other current liabilities includes a reduction of $315 million, representing funds previously deposited by Sanofi in an escrow account and held in that account as of December 31, 2019. Those funds were released in March 2020 following the signature of an agreement to settle the CVR litigation between Sanofi and the Trustee (American Stock Transfer & Trust Company LLC). A similar reduction was recognized in Other current financial assets to reflect the release of the escrow account.

Off Balance Sheet Commitments

Off Balance Sheet Commitments	6 Months Ended
Off Balance Sheet Commitments	Jun. 30, 2020
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Off Balance Sheet Commitments	B.13. OFF BALANCE SHEET COMMITMENTS Off balance sheet commitments to third parties arise under collaboration agreements entered into by Sanofi (see Note D.21.1. to the consolidated financial statements for the year ended December 31, 2019). Agreements signed during the first half of 2020 gave rise to the following new commitments: • Payments associated with projects in the research phase: €0.7 billion. • Payments contingent on the attainment of specified sales targets once a product reaches the market: €0.6 billion. • Potential milestone payments relating to development projects under collaboration agreements: €0.3 billion. The principal commitments entered into, amended or discontinued during the period are described below: ▪ On June 23, 2020, it was announced that the collaboration and license agreement between Sanofi Pasteur and Translate Bio on the development of mRNA vaccines for infectious diseases would be extended to include development of a novel mRNA vaccine for the virus responsible for COVID-19. Under the terms of the extended agreement, finalized on July 20, 2020, Translate Bio receive an upfront payment of $425 million to acquire (i) exclusive worldwide rights to develop, manufacture and commercialize infectious disease vaccines using Translate Bio technology and (ii) an equity interest in the form of 4.9 million shares of Translate Bio common stock, valued at $95 million at the quoted market price as of that date. In addition, Translate Bio will be eligible for potential future milestone and other payments of up to $1.4 billion. ▪

Litigation and Arbitration Proc

Litigation and Arbitration Proceedings	6 Months Ended
Litigation and Arbitration Proceedings	Jun. 30, 2020
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Litigation and Arbitration Proceedings	B.14. LITIGATION AND ARBITRATION PROCEEDINGS Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures. The matters discussed below constitute the most significant developments since publication of the disclosures concerning legal proceedings in the Company’s financial statements for the year ended December 31, 2019. B.14.1. PRODUCTS DEPAKINE ® PRODUCT LITIGATION IN FRANCE In July 2020, an Administrative Court recognized the liability of the French State in three legal proceedings initiated by families whose children were allegedly exposed in utero to Depakine ® . When assessing the State’s liability, the Court also ruled on the liability of the prescribers and Sanofi-Aventis France (SAF), considering that their respective roles should also be taken into account in each of these situations although neither was party to the proceedings and consequently in a position to present arguments and facts. The allocation of liability varies in each of these cases, depending on the period and the alleged damage. Sanofi is considering procedural options to challenge these rulings related to SAF’s liability. On July 1, 2020, a summons was filed before the civil court on behalf of several families against SAF and its insurer. Plaintiffs are notably arguing mental anguish and seeking compensation from SAF. In the criminal investigation on Depakine ® which has been pending before the Paris Civil Court since 2016, SAF is the object of a judicial supervision which is accompanied by the implementation of financial security guarantees in accordance with the rules of criminal procedure in France. It is not possible, at this stage, to assess reliably the outcome of these lawsuits or the potential financial impact on Sanofi. ZANTAC ® LITIGATION IN THE US In June 2020, the New Mexico Attorney General filed a complaint against Sanofi, the previous marketing authorization holders for branded OTC Zantac ® , a dozen generic manufacturers, and several retailers. The complaint brings claims for alleged violations of the New Mexico Unfair Practices Act, violations of the New Mexico False Advertising Act, violations of the New Mexico Public Nuisance Statute, common law public nuisance, and negligence. On June 6, 2020, Sanofi received a notice from the US Department of Justice Civil Division and US Attorney’s Office for the Eastern District of Pennsylvania of an investigation into allegations that pharmaceutical manufacturers violated the False Claims Act, 31 U.S.C. § 3729, in relation to the drug Zantac ® and ranitidine hydrochloride through alleged failure to disclose to the federal government information about the potential presence of N-Nitrosodimethylamine (NDMA). The notice requests information and documents from Sanofi including applications and communications with FDA. It is not possible, at this stage, to assess reliably the outcome of these lawsuits or the potential financial impact on Sanofi. ZANTAC ® LITIGATION IN CANADA In May 2020, a Class Action proceeding was filed in Ontario Superior Court relating to ranitidine and naming Sanofi Consumer Health Inc., Sanofi-Aventis Canada Inc., Sanofi et. al. as Defendants. Representative Plaintiffs claim that they suffered personal injury, including cancer, from the ingestion of ranitidine and are seeking general, special, statutory, punitive and aggravated damages in an unspecified amount. Additionally, they seek restitution for unjust enrichment in an amount equivalent to the purchase price of Zantac ® . On May 29, 2020, an amended Class Action Proceeding now naming Sanofi Consumer Health Inc. as a Defendant along with 21 other Defendants was filed in the British Columbia Supreme Court. The Representative Plaintiff is claiming on behalf of all Canadian residents damages, including personal injury, arising allegedly from the ingestion of ranitidine. General, special and punitive damages are being claimed in an unspecified amount. It is not possible, at this stage, to assess reliably the outcome of these lawsuits or the potential financial impact on Sanofi. B.14.2. PATENTS PRALUENT ® (ALIROCUMAB)-RELATED AMGEN PATENT LITIGATION IN EUROPE In the patent litigation in Italy, in June 2020, Amgen filed an interim proceeding with the Milan Court and requested a preliminary injunction on Praluent ® . PRALUENT ® (ALIROCUMAB)-RELATED AMGEN OPPOSITION AND PATENT LITIGATION IN JAPAN In April 2020, the Supreme Court denied Sanofi’s appeal in the invalidation action and the infringement proceeding. The injunction issued by the Tokyo District Court became enforceable and Sanofi complied. Praluent ® is no longer commercialized in Japan. JEVTANA ® (CABAZITAXEL)-RELATED PATENT LITIGATION IN THE US Jevtana ® is covered by five Orange Book listed patents U.S. 5,847,170, U.S. 7,241,907, U.S. 8,927,592, U.S. 10,583,110 and U.S. 10,716,777. In May and June 2020, Sanofi filed patent infringement suits under Hatch-Waxman against 12 generic filers asserting the ‘110 patent in the U.S. District Court for the District of Delaware. No trial has been scheduled yet. PLAVIX ® LITIGATION (COMMONWEALTH) IN AUSTRALIA In April 2020, the Commonwealth’s claim was dismissed. In May 2020, the Commonwealth filed a Notice of Appeal to the Full Court of the Federal Court. B.14.3. CONTINGENCIES ARISING FROM CERTAIN BUSINESS DIVESTITURES BOEHRINGER INGELHEIM (BI) RETAINED LIABILITIES Following BI’s request for arbitration regarding its refuted claim for indemnification in relation to Zantac ®

Other Operating Income And Expe

Other Operating Income And Expenses	6 Months Ended
Other Operating Income And Expenses	Jun. 30, 2020
Analysis of income and expense [abstract]
Other Operating Income and Expenses	B.15. OTHER OPERATING INCOME AND EXPENSES Other operating income amounted to €281 million in the first half of 2020 (versus €273 million in the first half of 2019), and Other operating expenses to €693 million (versus €466 million in the first half of 2019). The main items included in Other operating income in the first half of 2020 were income from pharmaceutical partners of €92 million (versus €36 million in the first half of 2019), of which €79 million came from Regeneron (versus €30 million in the first half of 2019, see table below); and gains on disposals of assets and operations of €147 million, primarily on divestments of mature products (versus €71 million in the first half of 2019). Other operating expenses for the first half of 2020 included €525 million of expenses relating to the alliance with Regeneron (versus €241 million in the first half of 2019), as shown in the table below. (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Income & expense related to (profit)/loss sharing of the Antibodies Alliance (341) (16) (253) Additional share of profit paid by Regeneron related to development costs 35 — 21 Regeneron commercial operating expenses reimbursement (176) (218) (449) Total: Antibody Alliance (482) (234) (681) Immuno-Oncology Alliance 44 30 62 Other (mainly Zaltrap®) (8) (7) (14) Other operating income/(expenses), net, related to Regeneron Alliance (446) (211) (633) of which amount presented in Other operating income 79 30 82

Restructuring Costs And Similar

Restructuring Costs And Similar Items	6 Months Ended
Restructuring Costs And Similar Items	Jun. 30, 2020
Analysis of income and expense [abstract]
Restructuring Costs and Similar Items	B.16. RESTRUCTURING COSTS AND SIMILAR ITEMS Restructuring costs and similar items comprise the following: (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Employee-related expenses 642 667 791 Expenses related to property, plant and equipment and to inventories 62 39 106 Compensation for early termination of contracts (other than contracts of employment) 11 3 49 Decontamination costs — 1 27 Other restructuring costs 43 37 89 Total 758 747 1,062 Restructuring costs in the first half of 2020 mainly reflect employee separation costs further to the announcement of plans to adapt Sanofi’s organization (primarily in Europe) in line with the new “Play-to-Win” strategic roadmap announced in December 2019. Restructuring costs in the first half of 2019 related to employee-related expenses associated with headcount adjustment plans, mainly in Europe and the United States.

Other Gains and Losses, and Lit

Other Gains and Losses, and Litigation	6 Months Ended
Other Gains and Losses, and Litigation	Jun. 30, 2020
Analysis of income and expense [abstract]
Other gains and losses, and litigation	B.17. OTHER GAINS AND LOSSES, AND LITIGATION Other gains and losses, and litigation for the first half of 2020 represent a net gain of €136 million, mainly comprising a gain on the sale of operations related to the Seprafilm product to Baxter for proceeds of €313 million. This compares with a net gain of €317 million in the first half of 2019, mainly relating to litigation.

Financial Expenses and Income

Financial Expenses and Income	6 Months Ended
Financial Expenses and Income	Jun. 30, 2020
Analysis of income and expense [abstract]
Financial expenses and Income	B.18. FINANCIAL EXPENSES AND INCOME An analysis of financial expenses and income is set forth below: (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Cost of debt (a) (166) (171) (318) Interest income (b) 66 82 146 Cost of net debt (100) (89) (172) Non-operating foreign exchange gains/(losses) 2 3 1 Unwinding of discounting of provisions (c) (6) (12) (25) Net interest cost related to employee benefits (32) (45) (87) Net interest expense on lease liabilities (d) (19) (20) (39) Other (12) 13 19 Net financial income/(expenses) (167) (150) (303) comprising: Financial expenses (198) (244) (444) Financial income 31 94 141 (a) Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: €58 million in the first half of 2020, €83 million in the first half of 2019, and €187 million over the whole of 2019. (b) Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: €37 million in the first half of 2020, €27 million in the first half of 2019, and €55 million over the whole of 2019. (c) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.). (d) Impact of IFRS 16 (Leases), see Note A.2.1. to the 2019 consolidated financial statements. The impact of the ineffective portion of hedging relationships was not material in either 2020 or 2019.

Income Tax Expense

Income Tax Expense	6 Months Ended
Income Tax Expense	Jun. 30, 2020
Income Taxes [Abstract]
Income Tax Expense	B.19. INCOME TAX EXPENSE Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States. The table below shows the allocation of income tax expense between current and deferred taxes: (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Current taxes (1,127) (828) (1,892) Deferred taxes 133 815 1,753 Total (994) (13) (139) Income before tax and investments accounted for using the equity method 9,941 962 2,822 The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows: (as a percentage) June 30, 2020 (6 months) (a) June 30, 2019 (6 months) (a) December 31, 2019 (12 months) Standard tax rate applicable in France 32.0 34.4 34.4 Difference between the standard French tax rate and the rates applicable to Sanofi (b) (20.2) (13.7) (22.9) Impact of commitments arising from business divestitures — (12.1) (6.2) Revisions to tax exposures and settlements of tax disputes 0.2 4.5 4.8 Fair value remeasurement of contingent consideration liabilities (0.1) (3.0) (2.6) Other (c) (1.9) (8.8) (2.6) Effective tax rate 10.0 1.3 4.9 (a) Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.). (b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. For 2020, the percentage is impacted by the difference between the normal French tax rate and the tax rate applicable to the sale of Regeneron shares. (c) For 2019, the percentage on the “Other” line is impacted by the reduction in Income before tax and investments accounted for using the equity method .

Segment Information

Segment Information	6 Months Ended
Segment Information	Jun. 30, 2020
Operating Segments [Abstract]
Segment information	B.20. SEGMENT INFORMATION As indicated in Note B.26. to the consolidated financial statements for the year ended December 31, 2019, Sanofi has three operating segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: Specialty Care (Dupixent ® , Multiple Sclerosis, Neurology, Other Inflammatory Diseases & Immunology, Rare Diseases, Oncology, and Rare Blood Disorders) and General Medicines (Diabetes, Cardiovascular, and Established Prescription Products), together with research, development and production activities dedicated to the Pharmaceuticals segment. This segment also includes associates whose activities are related to pharmaceuticals. Following the transaction of May 29, 2020, Regeneron is no longer an associate of Sanofi (see Note B.1.). Consequently, the Pharmaceuticals segment no longer includes Sanofi’s equity-accounted share of Regeneron’s profits for all periods presented in this note. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. Inter-segment transactions are not material. The costs of Sanofi’s global support functions (External Affairs, Finance, Human Resources, Legal Affairs, Information Solutions & Technologies, Sanofi Business Services, etc.) are mainly managed centrally at group-wide level. The costs of those functions are presented within the “Other” category. That category also includes other reconciling items such as retained commitments in respect of divested activities. In 2020, Sanofi adopted a new management reporting structure. This resulted in cost reallocations between the Pharmaceuticals, Consumer Healthcare, Vaccines segments and “Other” category, and product reallocations (mainly between Pharmaceuticals and Consumer Healthcare). Expenses relating to Medical Affairs, previously shown in the “Other” category, were reallocated to the Pharmaceuticals segment. B.20.1. SEGMENT RESULTS B.20.1.1. Analysis of net sales The table below sets forth net sales for the six months ended June 30, 2020 and June 30, 2019: (€ million) Europe United States Other countries June 30, 2020 Europe United States Other countries June 30, 2019 Pharmaceuticals 3,347 4,806 4,867 13,020 3,393 4,193 5,132 12,718 General Medicines 2,232 1,458 3,928 7,618 2,421 1,647 4,336 8,404 of which Lantus ® 281 474 662 1,417 306 568 658 1,532 Toujeo ® 188 143 165 496 167 139 125 431 Praluent ® 56 68 22 146 63 44 15 122 Multaq ® 12 135 7 154 20 135 6 161 Lovenox ® 298 15 317 630 385 18 287 690 Plavix ® 67 5 437 509 70 — 696 766 Generics 57 75 362 494 66 79 391 536 Specialty Care 1,115 3,348 939 5,402 972 2,546 796 4,314 of which Aubagio ® 231 775 62 1,068 204 645 54 903 Cerezyme ® 125 90 153 368 128 88 147 363 Myozyme/Lumizyme ® 193 178 101 472 195 162 97 454 Fabrazyme ® 98 206 109 413 90 199 107 396 Eloctate ® — 234 96 330 — 272 73 345 Jevtana ® 92 123 56 271 87 101 49 237 Dupixent ® 174 1,310 150 1,634 83 669 73 825 Consumer Healthcare 717 583 1,024 2,324 741 599 1,067 2,407 of which Allergy, Cough and Cold 177 214 249 640 184 187 246 617 Pain 271 98 266 635 275 93 273 641 Digestive 167 38 221 426 175 103 260 538 Nutritionals 62 23 223 308 67 19 214 300 Vaccines 281 491 1,064 1,836 317 609 968 1,894 of which Polio/Pertussis/Hib vaccines 162 183 714 1,059 157 192 639 988 Influenza vaccines 5 13 161 179 2 4 111 117 Total net sales 4,345 5,880 6,955 17,180 4,451 5,401 7,167 17,019 B.20.1.2. Business operating income Sanofi reports segment results on the basis of “Business operating income”, a non-GAAP financial measure used internally by the chief operating decision maker to measure the performance of each operating segment and to allocate resources. Following the transaction of May 29, 2020, Regeneron is no longer an associate of Sanofi (see Note B.1.). Consequently, “Business operating income” has been adjusted, and no longer includes Sanofi’s share of the net income of Regeneron. This means that the Share of profit/(loss) from investments accounted for using the equity method line in the table reconciling Operating income ( as shown in the income statement) to “Business operating income” no longer includes the equity-accounted share of profits from Regeneron. The comparatives presented for 2019 have been restated to reflect that adjustment. In addition, the gain arising on the divestment of the equity investment in Regeneron is not included in “Business operating income”, with the exception of the gain on the remeasurement of the 400,000 retained shares at market value at the transaction date. In addition, with effect from January 1, 2020 “Business operating income” includes depreciation charged against right-of-use assets recognized under IFRS 16 (Leases), applicable since January 1, 2019, and excludes rental expenses previously recognized under IAS 17. In the interests of consistency, “Business operating income” for the comparative periods of 2019 presented has been restated to include the effects of IFRS 16, and of certain expenses and income presented differently for segment reporting purposes to align on Sanofi’s new 2020 management reporting structure (see Note B.20., “Segment Information”, above). “Business operating income” is derived from Operating income , adjusted as follows: • the amounts reported in the line items Restructuring costs and similar items, Fair value remeasurement of contingent consideration (relating to business combinations or divestments) and Other gains and losses, and litigation are eliminated; • amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) are eliminated; • the share of profits/losses from investments accounted for using the equity method is added, excluding Regeneron up to and including May 29, 2020 (see Note B.1.); • net income attributable to non-controlling interests is deducted; • other acquisition-related effects (primarily the workdown of acquired inventories remeasured at fair value at the acquisition date, and the impact of acquisitions on investments accounted for using the equity method) are eliminated; • restructuring costs relating to investments accounted for using the equity method are eliminated; and • the gain on the divestment of Regeneron shares dated May 29, 2020 is eliminated (this elimination does not include the gain on the remeasurement of the 400,000 retained shares at market value as of that date). Segment results are shown in the table below: June 30, 2020 (6 months) (€ million) Pharmaceuticals Consumer Healthcare Vaccines Other Total Net sales 13,020 2,324 1,836 — 17,180 Other revenues 70 30 474 — 574 Cost of sales (3,427) (770) (1,184) (126) (5,507) Research and development expenses (2,143) (61) (324) (164) (2,692) Selling and general expenses (2,472) (760) (386) (989) (4,607) Other operating income and expenses (150) 21 4 (130) (255) Share of profit/(loss) from investments accounted for using the equity method (a) 4 7 — — 11 Net income attributable to non-controlling interests (17) (4) — — (21) Business operating income 4,885 787 420 (1,409) 4,683 (a) “Business operating income” no longer includes Sanofi’s equity-accounted share of Regeneron’s net profits (see definition above, and Note B.1.). June 30, 2019 (6 months) (€ million) Pharmaceuticals Consumer Healthcare Vaccines Other Total Net sales 12,718 2,407 1,894 — 17,019 Other revenues 103 27 544 — 674 Cost of sales (3,239) (783) (1,255) (105) (5,382) Research and development expenses (2,423) (71) (295) (183) (2,972) Selling and general expenses (2,679) (760) (374) (1,022) (4,835) Other operating income and expenses (228) 105 (6) (64) (193) Share of profit/(loss) from investments accounted for using the equity method (a) 4 6 — — 10 Net income attributable to non-controlling interests (12) (3) — — (15) Business operating income (b) 4,244 928 508 (1,374) 4,306 (a) “Business operating income” no longer includes Sanofi’s equity-accounted share of Regeneron’s net profits (see definition above, and Note B.1.). (b) Restated to exclude (i) Sanofi’s share of net profits from the investment in Regeneron (see above); and to include (i) the effects of IFRS 16 and (ii) the effect of certain expenses and income being presented differently for segment reporting purposes to align on Sanofi’s new 2020 management reporting structure. December 31, 2019 (12 months) (€ million) Pharmaceuticals Consumer Healthcare Vaccines Other Total Net sales 25,700 4,695 5,731 — 36,126 Other revenues 173 57 1,275 — 1,505 Cost of sales (6,750) (1,599) (3,372) (252) (11,973) Research and development expenses (4,850) (149) (639) (380) (6,018) Selling and general expenses (5,442) (1,529) (823) (2,089) (9,883) Other operating income and expenses (625) 193 — 50 (382) Share of profit/(loss) from investments accounted for using the equity method (a) 5 (5) 9 — 9 Net income attributable to non-controlling interests (29) (6) — — (35) Business operating income (b) 8,182 1,657 2,181 (2,671) 9,349 (a) “Business operating income” no longer includes Sanofi’s equity-accounted share of Regeneron’s net profits (see definition above, and Note B.1.). (b) Restated to exclude (i) Sanofi’s share of net profits from the investment in Regeneron (see above); and to include (i) the effects of IFRS 16 and (ii) the effect of certain expenses and income being presented differently for segment reporting purposes to align on Sanofi’s new 2020 management reporting structure. The table below, presented in compliance with IFRS 8, shows a reconciliation between “Business operating income” and Income before tax and investments accounted for using the equity method: (€ million) June 30, 2020 (6 months) June 30, 2019 (f) (6 months) December 31, 2019 (f) (12 months) Business operating income 4,683 4,306 9,349 Share of profit/(loss) from investments accounted for using the equity method (a)/(b) (11) (10) (9) Net income attributable to non-controlling interests (c) 21 15 35 Amortization and impairment of intangible assets (1,206) (2,956) (5,750) Fair value remeasurement of contingent consideration 54 190 238 Expenses arising from the impact of acquisitions on inventories (36) (3) (3) Restructuring costs and similar items (758) (747) (1,062) Other gains and losses, and litigation (d) 136 317 327 Gain on sale of Regeneron shares on May 29, 2020 (e) 7,225 — — Operating income 10,108 1,112 3,125 Financial expenses (198) (244) (444) Financial income 31 94 141 Income before tax and investments accounted for using the equity method 9,941 962 2,822 (a) Excludes (i) restructuring costs and (ii) expenses arising from the impact of acquisitions on investments accounted for using the equity method. (b) Following the transaction of May 29, 2020, “Business operating income” no longer includes Sanofi’s equity-accounted share of Regeneron’s net profits (see Note B.1.). Consequently, this line does not include Sanofi’s share of net profits from the investment in Regeneron up to and including that date. (c) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (d) For the six months ended June 30, 2020, this line mainly comprises the gain on the sale of operations related to the Seprafilm product to Baxter. (e) This line includes the gain on the sale of (i) 13 million shares of Regeneron common stock in the registered public offering and (ii) the 9.8 million shares repurchased by Regeneron, but does not include the gain arising from the remeasurement of the 400,000 retained shares at market value of May 29, 2020. (f) Business operating income as presented in the 2019 financial statements has been restated to exclude (i) Sanofi’s share of net profits from the investment in Regeneron, amounting to €159 million in the six months ended June 30, 2019 and €411 million in the year ended December 31, 2019 (see above); and to include (i) the effects of IFRS 16 and (ii) the effect of certain expenses and income being presented differently for segment reporting purposes to align on Sanofi’s new 2020 management reporting structure. B.20.2. OTHER SEGMENT INFORMATION The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity method, (ii) acquisitions of property, plant and equipment, and (iii) acquisitions of intangible assets. The principal investments accounted for using the equity method in the Pharmaceuticals segment are entities majority owned by BMS (up to and including February 29, 2020, see Note B.5.), and Infraserv GmbH & Co. Höchst KG. Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period. June 30, 2020 (€ million) Pharmaceuticals Consumer Healthcare Vaccines Total Investments accounted for using the equity method 149 3 44 196 Acquisitions of property, plant and equipment 294 27 181 502 Acquisitions of other intangible assets 153 6 21 180 June 30, 2019 (€ million) Pharmaceuticals Consumer Healthcare Vaccines Total Investments accounted for using the equity method (a) 327 20 32 379 Acquisitions of property, plant and equipment (b) 383 28 243 654 Acquisitions of other intangible assets 124 7 56 187 (a) This line has been restated to eliminate Sanofi’s equity investment in Regeneron (see Note B.20.) . (b) Includes the effect of restatements needed to align on Sanofi’s new 2020 management reporting structure. December 31, 2019 (€ million) Pharmaceuticals Consumer Healthcare Vaccines Total Investments accounted for using the equity method (a) 205 4 40 249 Acquisitions of property, plant and equipment (b) 773 88 462 1,323 Acquisitions of other intangible assets 321 51 121 493 (a) This line has been restated to eliminate Sanofi’s equity investment in Regeneron (see Note B.20.) . (b) Includes the effect of restatements needed to align on Sanofi’s new 2020 management reporting structure. B.20.3. INFORMATION BY GEOGRAPHICAL REGION The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16. June 30, 2020 (€ million) Total Europe of which France North of which United States Other countries Net sales 17,180 4,345 1,061 6,151 5,880 6,684 Non-current assets: • property, plant and equipment 9,368 5,683 3,067 2,756 2,153 929 • goodwill 45,254 — — — — — • other intangible assets 17,021 6,544 — 8,838 — 1,639 June 30, 2019 (€ million) Total Europe of which France North of which United States Other countries Net sales 17,019 4,351 1,099 5,685 5,401 6,983 Non-current assets: • property, plant and equipment 9,606 5,781 3,120 2,791 2,250 1,034 • goodwill 44,418 — — — — — • other intangible assets 19,098 7,439 — 9,485 — 2,174 December 31, 2019 (€ million) Total Europe of which France North of which United States Other countries Net sales 36,126 8,852 2,261 13,370 12,756 13,904 Non-current assets: • property, plant and equipment 9,717 5,824 3,141 2,862 2,264 1,031 • goodwill 44,519 — — — — — • other intangible assets 16,572 6,941 — 7,825 — 1,806 As stated in Notes B.6.1. and D.5. to the consolidated financial statements for the year ended December 31, 2019, goodwill is not allocated by geographical region. B.20.4. PRINCIPAL CUSTOMERS AND CREDIT RISK Sanofi’s three largest customers respectively accounted for approximately 9%, 6% and 5% of consolidated net sales in the first half of 2020, mostly in the Pharmaceuticals segment (versus approximately 9%, 6% and 4% in the first half of 2019).

Events subsequent to June 30, 2

Events subsequent to June 30, 2020	6 Months Ended
Events subsequent to June 30, 2020	Jun. 30, 2020
Events After Reporting Period [Abstract]
Events Subsequent To June 30, 2020	Early July 2020, Sanofi entered into an exclusive license agreement with Kiadis Pharma N.V. , a clinical-stage biopharmaceutical company developing natural killer (NK) cell therapies for patients with life-threatening diseases, for Kiadis’ previously undisclosed K-NK004 program. The agreement covers Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutic for combination with anti-CD38 monoclonal antibodies including Sarclisa ® , Sanofi’s recently approved therapy for patients with multiple myeloma. Sanofi also obtained exclusive rights to use Kiadis’ K-NK platform for two undisclosed pre-clinical programs. As part of the agreement, Kiadis will receive a €17.5 million upfront payment and will be entitled to receive up to €857.5 million upon Sanofi attaining preclinical, clinical, regulatory and commercial milestones. Kiadis will also receive double-digit royalties based on commercial sales of approved products resulting from the agreement. Early July 2020, Sanofi and Kymera Therapeutics Inc. signed a multi-program strategic collaboration agreement to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage program. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential milestones, as well as royalty payments. Kymera retains the option to participate in US development and commercialization for both programs subject to its having an equal share in the costs, profits and losses, and to co-promote partnered products in the US.

Basis of Preparation of the H_2

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Corporate Information And Statement Of IFRS Compliance [Abstract]
International Financial Reporting Standards (IFRS)	The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2019. The accounting policies used in the preparation of the consolidated financial statements as of June 30, 2020 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2020 are available via the following web link: https://www.efrag.org/Endorsement The accounting policies applied effective January 1, 2020 are identical to those presented in the consolidated financial statements for the year ended December 31, 2019. During 2018, the IASB published a number of amendments that are mandatorily applicable from January 1, 2020 onwards. These include “Definition of a Business” (an amendment to IFRS 3), issued October 22, 2018, which applies prospectively to business combinations completed on or after January 1, 2020. Applying this amendment did not have a material impact on the condensed consolidated half-year financial statements for the six months ended June 30, 2020. As a reminder, Sanofi early adopted the amendment to IFRS 9 relating to interest rate benchmark reform in its consolidated financial statements for the year ended December 31, 2019.
Use of Estimates	The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include: • amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions; • impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method; • the valuation of goodwill and the valuation and useful life of acquired intangible assets; • the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable; • the measurement of equity investments in unquoted entities; • the measurement of financial assets at amortized cost; • the amount of post-employment benefit obligations; • the amount of provisions for restructuring, litigation, tax risks (other than those related to income taxes) and environmental risks; and • the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.
Seasonal Trends	Sanofi’s activities are not subject to significant seasonal fluctuations.
Consolidation and Foreign Currency Translation of the Financial Statements of Subsidiaries in Hyperinflationary Economies	In 2020, Sanofi is continuing to account for subsidiaries in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. In 2018, following a change to the foreign exchange system, the “DICOM” rate was replaced by the “PETRO” rate (with a floating US dollar/bolivar parity) and the strong bolivar (“VEF”) by a new currency known as the sovereign bolivar (“VES”), reflecting a 1-for-100,000 devaluation. Consequently, the contribution of the Venezuelan subsidiaries to the Sanofi consolidated financial statements is immaterial. In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy, and applied IAS 29. The impact on the consolidated income statement of adjustments required for the application of IAS 29 to Argentinean hyperinflation as of June 30, 2020 is an expense of €16 million; the impact on balance sheet line items as of that date is immaterial.
Fair Value of Financial Instruments	Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: • Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); • Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; • Level 3: valuation techniques in which not all important inputs are derived from observable market data. The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Market data Valuation model Exchange rate Interest rate Volatilities B.6. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Amortized cost/ Peer comparison (primarily) If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used. B.6. Financial assets at fair value (contingent consideration receivable) Fair value 3 Revenue-based approach Under IFRS 9, contingent consideration receivable on a divestment is a financial asset. The fair value of such assets is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2019. B.6. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. B.6. Financial assets recognized under the fair value option (a) Fair value 1 Market value Quoted market price N/A B.10. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market> 1 year: Mid Zero Coupon N/A B.10. Interest rate swaps Fair value 2 Revenue-based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.9. Investments in mutual funds Fair value 1 Market value Net asset value N/A B.9. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. B.9. Debt Amortized cost (b) N/A N/A In the case of debt with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For debt with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). B.9. Lease liabilities Amortized cost N/A N/A Future lease payments are discounted using the incremental borrowing rate B.11. Liabilities related to business combinations and to non-controlling interests (CVRs) Fair value 1 Market value Quoted market price N/A B.11. Liabilities related to business combinations and to non-controlling interests (other than CVRs) Fair value (c) 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) These assets are held to fund a deferred compensation plan offered to certain employees. (b) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s). (c) For business combinations completed prior to application of the revised IFRS 3, contingent consideration is recognized when payment becomes probable. See Note B.3.1. to the consolidated financial statements for the year ended December 31, 2019.
New Pronouncements Issued by IASB and Applicable from June 2020 or Later	On May 28, 2020, the IASB issued “Covid-19-Related Rent Concessions”, an amendment to IFRS 16. The amendment, which is applicable from June 1, , 2020 (subject to endorsement by the European Union), allows lessees not to account for rent concessions as lease modifications if they are a direct consequence of Covid-19 and meet certain conditions. Sanofi does not expect a material impact from the application of this amendment. On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1. On May 14, 2020, the IASB issued “Reference to the Conceptual Framework”, an amendment to IFRS 3; Proceeds before Intended Use”, an amendment to IAS 16; “Onerous Contracts – Cost of Fulfilling a Contract”, an amendment to IAS 37; and “Annual Improvements to IFRS standards 2018-2020”. Sanofi does not expect a material impact from those amendments, which are applicable at the earliest from January 1, 2022 (subject to endorsement by the European Union). Sanofi will not early adopt those amendments.
COVID-19 Pandemic	Covid-19, confirmed as a pandemic by the World Health Organisation on March 11, 2020, has led to a global health crisis. Sanofi has assessed the impact of the uncertainties created by the Covid-19 pandemic. As of June 30, 2020, those uncertainties have not appreciably called into question the estimates and assumptions made by management (see Note A.2.). Sanofi will continue to reassess those estimates and assumptions as the situation evolves. Effect of the Covid-19 pandemic on the valuation of goodwill and intangible assets In accordance with IAS 36 (Impairment of Assets), Sanofi conducts impairment tests on goodwill allocated to each of its Cash Generating Units and on other intangible assets not yet available for use (such as capitalized in process research and development) on an annual basis, regardless of whether there is an indication that they might have become impaired. The most recent impairment tests were conducted as of December 31, 2019 (see Note D.5. to the consolidated financial statements for the year ended December 31, 2019). In light of the Covid-19 pandemic, in preparing the 2020 half-year consolidated financial statements Sanofi assessed the following indicators, and found no indication that the assets in question might have become impaired as a result of the pandemic: – quoted market price of shares in Sanofi and peers in the healthcare sector; – trends in interest rates and risk premiums; – trends in sales and earnings for each CGU during the first half of 2020; – 2020 full-year sales and operating profit forecasts for each CGU; – progress on research and development programs; – supply chain and activity levels at Sanofi’s industrial facilities; and – changes to long-term business plans. In addition, the goodwill impairment tests conducted in 2019 showed that for each CGU, the recoverable amount was substantially higher than the carrying amount (see Note D.5. to the consolidated financial statements for the year ended December 31, 2019). Consequently, in accordance with IAS 36, the Cash Generating Units to which goodwill is allocated have not been tested for impairment. Finally, Sanofi has conducted impairment tests related to the specific circumstances of some intangible assets with no direct link to the Covid-19 pandemic; the results of those tests are described in Note B.4. Effect of the Covid-19 pandemic on accounts receivable As of June 30, 2020, Sanofi analysed indicators that its accounts receivable might have become impaired, such as the ageing of gross receivables and the amount of doubtful receivables (see Note B.7). Nothing was identified that would indicate a material increase in expected credit risk, especially as regards Sanofi’s principal customers (see Note B.20.4). Effect of the Covid-19 pandemic on the liquidity position The Covid-19 pandemic has not had a negative impact on Sanofi’s liquidity position. Effect of the Covid-19 pandemic on the presentation of the income statement The effects of the Covid-19 pandemic are presented in the relevant line items of the income statement, according to the function or nature of the income or expense.

Basis of Preparation of the H_3

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract]
Disclosure of detailed information about financial instruments	The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Market data Valuation model Exchange rate Interest rate Volatilities B.6. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Amortized cost/ Peer comparison (primarily) If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used. B.6. Financial assets at fair value (contingent consideration receivable) Fair value 3 Revenue-based approach Under IFRS 9, contingent consideration receivable on a divestment is a financial asset. The fair value of such assets is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2019. B.6. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. B.6. Financial assets recognized under the fair value option (a) Fair value 1 Market value Quoted market price N/A B.10. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market> 1 year: Mid Zero Coupon N/A B.10. Interest rate swaps Fair value 2 Revenue-based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.9. Investments in mutual funds Fair value 1 Market value Net asset value N/A B.9. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. B.9. Debt Amortized cost (b) N/A N/A In the case of debt with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For debt with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). B.9. Lease liabilities Amortized cost N/A N/A Future lease payments are discounted using the incremental borrowing rate B.11. Liabilities related to business combinations and to non-controlling interests (CVRs) Fair value 1 Market value Quoted market price N/A B.11. Liabilities related to business combinations and to non-controlling interests (other than CVRs) Fair value (c) 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) These assets are held to fund a deferred compensation plan offered to certain employees. (b) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s). (c) For business combinations completed prior to application of the revised IFRS 3, contingent consideration is recognized when payment becomes probable. See Note B.3.1. to the consolidated financial statements for the year ended December 31, 2019.

Changes in the Scope of Conso_2

Changes in the Scope of Consolidation Due to Acquisitions and Divestments (Tables)	6 Months Ended
	Jun. 30, 2020
Business Combinations 1 [Abstract]
Summary of Final Purchase Price Allocation	The provisional purchase price allocation, as presented in the table below, resulted in the recognition of goodwill of €901 million: (€ million) Fair value at acquisition date Intangible assets other than goodwill 1,549 Other current and non-current assets and liabilities 41 Net deferred tax position (245) Net assets of Synthorx 1,345 Goodwill 901 Purchase price 2,246

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
Property, Plant and Equipment (Tables)	Jun. 30, 2020
Property, plant and equipment [abstract]
Summary of Acquisitions and Capitalized Interest by Operating Segment	The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2020: (€ million) June 30, 2020 December 31, 2019 Acquisitions 389 1,261 Pharmaceuticals 234 846 Industrial facilities 196 682 Research sites 37 87 Other 1 77 Vaccines 128 405 Consumer Healthcare 27 10 Capitalized interest 6 14

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
Goodwill and Other Intangible Assets (Tables)	Jun. 30, 2020
Intangible Assets [Abstract]
Schedule of Movements in Other Intangible Assets	Movements in other intangible assets during the first half of 2020 were as follows: (€ million) Acquired R&D Products, trademarks and other rights Software Total other intangible assets Gross value at January 1, 2020 5,730 63,953 1,698 71,381 Changes in scope of consolidation (a) 1,417 132 — 1,549 Acquisitions and other increases 115 38 65 218 Disposals and other decreases (17) (106) (12) (135) Currency translation differences (28) (118) (11) (157) Transfers (b) (52) 52 (2) (2) Gross value at June 30, 2020 7,165 63,951 1,738 72,854 Accumulated amortization and impairment at January 1, 2020 (3,396) (50,314) (1,099) (54,809) Amortization expense — (895) (62) (957) Impairment losses, net of reversals (c) (321) (2) — (323) Disposals and other decreases 17 105 13 135 Currency translation differences 2 107 9 118 Transfers 18 (15) — 3 Accumulated amortization and impairment at June 30, 2020 (3,680) (51,014) (1,139) (55,833) Carrying amount at January 1, 2020 2,334 13,639 599 16,572 Carrying amount at June 30, 2020 3,485 12,937 599 17,021 (a) See Note B.1. (b) This line mainly represents Sarclisa ® (Oncology) and MenQuadfi TM (Vaccines), which came into commercial use during the period. (c) See Note B.4.

Investments Accounted for Usi_2

Investments Accounted for Using the Equity Method (Tables)	6 Months Ended
Investments Accounted for Using the Equity Method (Tables)	Jun. 30, 2020
Interests In Other Entities [Abstract]
Summary of Investments in Associates and Joint Ventures	Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2019), and comprise: (€ million) % interest June 30, 2020 December 31, 2019 Regeneron Pharmaceuticals, Inc. (a) — 3,342 Infraserv GmbH & Co. Höchst KG (b) 31.2 62 70 Entities and companies managed by Bristol-Myers Squibb (c) 100.0 — 37 Other investments — 134 142 Total 196 3,591 (a) Following the transaction of May 29, 2020 as described in Note B.1. above, which resulted in the divestment of 22.8 million Regeneron shares, Sanofi no longer exercises significant influence over Regeneron. As of that date, Sanofi retained 0.4 million Regeneron shares, classified in the “Equity instruments at fair value through other comprehensive income” category (see Note B.6.) (b) Joint venture. (c) On February 29, 2020, Sanofi acquired from Bristol-Myers Squibb the remaining 50.1% equity interest not yet held by Sanofi in the three partnerships that organize the commercialization of Plavix ® in the United States and Puerto Rico, for a total consideration of $12 million. This acquisition was accounted for in accordance with IFRS 3 (Business Combinations).
Summary of Principal Transactions and Balances with Related Parties	The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below: (€ million) June 30, 2020 June 30, 2019 December 31, 2019 Sales (a) 52 16 24 Royalties and other income (a) 65 153 270 Accounts receivable and other receivables 7 160 151 Purchases and other expenses (including research expenses) (a) 605 608 1,334 Accounts payable and other payables 5 373 342 (a) For the six months ended June 30, 2020, these amounts include transactions between Sanofi and Regeneron for the period from January 1 through May 29, 2020. The table above does not include the repurchase by Regeneron of its own shares from Sanofi (see Note B.1.).

Other Non-Current Assets (Table

Other Non-Current Assets (Tables)	6 Months Ended
Other Non-Current Assets (Tables)	Jun. 30, 2020
Subclassifications of assets, liabilities and equities [abstract]
Summary of Other Non-current Assets	Other non-current assets comprise: (€ million) June 30, 2020 December 31, 2019 Equity instruments at fair value through other comprehensive income 872 380 Debt instruments at fair value through other comprehensive income 439 403 Other financial assets at fair value through profit or loss 812 892 Pre-funded pension obligations 156 155 Long-term prepaid expenses 103 115 Long-term loans and advances and other non-current receivables 616 685 Derivative financial instruments 33 37 Total 3,031 2,667

Accounts Receivable (Tables)

Accounts Receivable (Tables)	6 Months Ended
Accounts Receivable (Tables)	Jun. 30, 2020
Subclassifications of assets, liabilities and equities [abstract]
Summary of Accounts Receivable	Accounts receivable break down as follows: (€ million) June 30, 2020 December 31, 2019 Gross value 7,379 8,090 Allowances (176) (153) Carrying amount 7,203 7,937
Summary of Gross Value of Overdue Receivables	The table below shows the ageing profile of overdue accounts receivable, based on gross value: (€ million) Overdue accounts gross value Overdue by <1 month Overdue by 1-3 months Overdue by 3-6 months Overdue by 6-12 months Overdue by > 12 months June 30, 2020 633 210 208 81 29 105 December 31, 2019 642 269 171 61 36 105

Consolidated Shareholders' Eq_2

Consolidated Shareholders' Equity (Tables)	6 Months Ended
Consolidated Shareholders' Equity (Tables)	Jun. 30, 2020
Share Capital, Reserves And Other Equity Interest [Abstract]
Summary of Treasury Shares Held	Treasury shares held by Sanofi are as follows: Number of shares % of share capital June 30, 2020 2.59 0.207 % December 31, 2019 0.02 0.002 % June 30, 2019 0.02 0.002 % January 1, 2019 1.94 0.156 %
Summary of Characteristics of Employee Share Ownership Plans Awarded	Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2019. The principal features of the plans awarded in 2020 are set forth below: 2020 Type of plan Performance share plan Date of Board meeting approving the plan April 28, 2020 Total number of shares subject to a 3-year service period 3,340,501 Fair value per share awarded (a) 82.36 Fair value of plan at the date of grant (€ million) 275 (a) Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.
Summary of Number of Restricted Shares Not Yet Fully Vested	The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below: June 30, 2020 June 30, 2019 Total expense for restricted share plans (€ million) 113 128 Number of shares not yet fully vested 10,900,815 11,251,318 Under 2020 plans 3,340,501 — Under 2019 plans 3,545,507 3,797,582 Under 2018 plans 4,014,807 4,252,339 Under 2017 plans — 3,201,397
Summary of Expense Recognized Through Equity for Stock Option Plans	The table below shows, for each of the periods reported, the expense recognized through equity for stock option plans: (€ million) June 30, 2020 June 30, 2019 Expense recognized through equity — 3
Summary of Options Outstanding and Exercisable	The table below provides summary information about options outstanding and exercisable as of June 30, 2020: Range of exercise prices per share Outstanding Exercisable Number of options Weighted average residual life (years) Weighted average exercise price per share (€) Number of options Weighted average exercise price per share (€) From €50.00 to €60.00 per share 277,506 1.32 54.28 277,506 54.28 From €60.00 to €70.00 per share 220,000 7.85 65.84 — — From €70.00 to €80.00 per share 1,591,528 4.60 74.11 1,371,528 73.69 From €80.00 to €90.00 per share 712,804 5.85 89.19 384,964 89.38 Total 2,801,838 2,033,998
Summary of Number of Shares Used to Compute Diluted Earnings Per Share	Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares. (million) June 30, 2020 June 30, 2019 December 31, 2019 Average number of shares outstanding 1,251.7 1,247.2 1,249.9 Adjustment for stock options with dilutive effect 0.4 1.0 0.8 Adjustment for restricted shares 6.1 6.5 6.4 Average number of shares used to compute diluted earnings per share 1,258.2 1,254.7 1,257.1
Summary of Movements within Other Comprehensive Income	Movements within other comprehensive income are shown below: (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Actuarial gains/(losses): ▪ Actuarial gains/(losses) excluding investments accounted for using the equity method (146) (535) (377) ▪ Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes — — (5) ▪ Tax effects (19) 155 161 Equity instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) (a) 312 19 26 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) (13) 15 80 ▪ Tax effects (70) (38) (48) Items not subsequently reclassifiable to profit or loss 64 (384) (163) Debt instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) (b) 4 28 28 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects (1) (5) (5) Cash flow hedges: ▪ Change in fair value (excluding investments accounted for using the equity method) (c) 29 (15) (13) ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects (9) 4 4 Change in currency translation differences: ▪ Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method) (c) (590) 462 850 ▪ Currency translation differences (investments accounted for using the equity method) 24 23 64 ▪ Currency translation differences related to the investment in Regeneron and reclassified to profit or loss (d) (318) — — ▪ Hedges of net investments in foreign operations (60) (75) (163) ▪ Tax effects 19 18 48 Items subsequently reclassifiable to profit or loss (902) 440 813 (a) In 2020, includes a negative movement of €53 million for a change in the fair value of the equity instrument derivatives (collars) on shares in Dexcom, Inc contracted by Sanofi in 2019 and designated as a fair value hedge. (b) There were no reclassifications to profit or loss in the first half of 2020 or in 2019. (c) Includes reclassifications to profit or loss: €1 million in the first half of 2020 and €27 million in 2019 (of which €20 million was reclassified in the first half of 2019). (d) Amount of cumulative currency translation differences associated with the equity investment in Regeneron, reclassified to profit or loss in accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates).

Debt, Cash and Cash Equivalen_2

Debt, Cash and Cash Equivalents (Tables)	6 Months Ended
Debt, Cash and Cash Equivalents (Tables)	Jun. 30, 2020
Financial Instruments [Abstract]
Summary of Changes in Financial Position	Changes in financial position during the period were as follows: (€ million) June 30, 2020 December 31, 2019 Long-term debt 20,404 20,131 Short-term debt and current portion of long-term debt 3,329 4,554 Interest rate and currency derivatives used to manage debt (173) (117) Total debt 23,560 24,568 Cash and cash equivalents (15,969) (9,427) Interest rate and currency derivatives used to manage cash and cash equivalents 89 (34) Net debt (a) 7,680 15,107 (a) Net debt does not include lease liabilities, which amounted to €1,195 million as of June 30, 2020 and €1,248 million as of December 31, 2019.
Summary of Reconciliation of Carrying Amount to Value on Redemption	A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2020 is shown below: (€ million) Value on redemption Carrying amount at June 30, 2020 Amortized cost Adjustment to debt measured at fair value June 30, 2020 December 31, 2019 Long-term debt 20,404 77 (53) 20,428 20,180 Short-term debt and current portion of long-term debt 3,329 2 (2) 3,329 4,553 Interest rate and currency derivatives used to manage debt (173) — 29 (144) (86) Total debt 23,560 79 (26) 23,613 24,647 Cash and cash equivalents (15,969) — — (15,969) (9,427) Interest rate and currency derivatives used to manage cash and cash equivalents 89 — — 89 (34) Net debt (a) 7,680 79 (26) 7,733 15,186 (a) Net debt does not include lease liabilities, which amounted to €1,195 million as of June 30, 2020 and €1,248 million as of December 31, 2019.
Summary of Debt by Type Valuation of Redemption	The table below shows an analysis of net debt by type, at value on redemption: (€ million) June 30, 2020 December 31, 2019 non-current current Total non-current current Total Bond issues 20,340 1,890 22,230 20,128 4,079 24,207 Other bank borrowings 75 1,131 1,206 40 156 196 Other borrowings 13 1 14 13 12 25 Bank credit balances — 307 307 — 305 305 Interest rate and currency derivatives used to manage debt — (144) (144) — (86) (86) Total debt 20,428 3,185 23,613 20,181 4,466 24,647 Cash and cash equivalents — (15,969) (15,969) — (9,427) (9,427) Interest rate and currency derivatives used to manage cash and cash equivalents — 89 89 (6) (28) (34) Net debt 20,428 (12,695) 7,733 20,175 (4,989) 15,186
Summary of Market Value of Net Debt	The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows: (€ million) June 30, 2020 December 31, 2019 Market value 9,126 16,370 Value on redemption 7,733 15,186

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	6 Months Ended
Derivative Financial Instruments (Tables)	Jun. 30, 2020
Financial Instruments [Abstract]
Summary of Operating Currency Hedging Instruments	The table below shows operating currency hedging instruments in place as of June 30, 2020. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2020 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 3,251 15 – – – 3,251 15 of which US dollar 1,070 7 – – – 1,070 7 of which Chinese yuan renminbi 493 1 – – – 493 1 of which Singapore dollar 203 — – – – 203 — of which Japanese yen 182 4 – – – 182 4 of which Saudi riyal 158 — – – – 158 — Forward currency purchases 1,552 (8) – – – 1,552 (8) of which US dollar 537 (1) – – – 537 (1) of which Singapore dollar 487 (3) – – – 487 (3) of which Canadian dollar 68 — – – – 68 — of which Korean won 46 — – – – 46 — of which Japanese yen 41 — – – – 41 — Total 4,803 7 – – – 4,803 7
Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated	The table below shows financial currency hedging instruments in place as of June 30, 2020. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2020 (€ million) Notional amount Fair value Maximum expiry date Forward currency sales 5,213 88 of which US dollar 3,660 (a) 87 2020 of which Japanese yen 320 2 2020 of which Australian dollar 225 (1) 2020 Forward currency purchases 10,824 (39) of which US dollar 7,056 (b) (19) 2021 of which Singapore dollar 2,443 (c) (11) 2021 of which Japanese yen 384 (4) 2020 Total 16,037 49 (a) Includes forward sales with a notional amount of $3,615 million expiring in 2020, designated as a hedge of Sanofi’s net investment in Bioverativ. As of June 30, 2020, the fair value of these forward contracts represented an asset of €88 million; the opposite entry was recognized in Other comprehensive incom e, with the impact on financial income and expense being immaterial. (b) Includes forward purchases with a notional amount of $4,000 million expiring in 2020, designated as a fair value hedge of USD bond issues against fluctuations in the EUR/USD spot rate. As of June 30, 2020, the fair value of these contracts represented an asset of €87 million, with €21 million of that amount credited to Other comprehensive income to recognise the hedging cost. (c) Includes forward purchases with a notional amount of SGD 2,000 million expiring in 2020 and 2021, designated as fair value hedges of an equivalent portion of an intra-group loan against fluctuations in the EUR/SGD spot rate. As of June 30, 2020, the fair value of these contracts represented a liability of €2 million, with €12 million credited to Other comprehensive income to recognise the hedging cost.
Disclosure of Instruments	The table below shows instruments of this type in place as of June 30, 2020: Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2020 2021 2022 2023 2024 Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized Eonia / receive 0.06% — — 2,000 — — 2,000 30 2,000 30 — — — pay -0.57% / receive capitalized Eonia — — 600 — — 600 3 — — 600 3 — pay 1.81% / receive 3-month USD Libor 445 — — — — 445 (4) — — 445 (4) (1) pay 3-month USD Libor / receive 2.22% 445 — — — — 445 5 445 5 — — — receive capitalized Eonia / pay 1.48% (a) — — 42 57 — 99 (5) 99 (5) — — — Total 890 — 2,642 57 — 3,589 29 2,544 30 1,045 (1) (1) (a) These interest rate swaps hedge fixed-rate bonds with a nominal of €99 million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within “Loans, advances and other long-term receivables”. B.10.3. EQUITY DERIVATIVES During 2019, Sanofi contracted derivative instruments (collars) on 593,712 shares of Dexcom, Inc. The collars were designated as fair value hedges of the Dexcom shares, and had a negative fair value as of June 30, 2020 of €57 million, recognized in full in Other comprehensive income .

Liabilities Related to Busine_2

Liabilities Related to Business Combinations and to Non-Controlling Interest (Tables)	6 Months Ended
	Jun. 30, 2020
Business Combinations 1 [Abstract]
Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests	Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2020 are shown below: (€ million) Bayer contingent consideration arising from the acquisition of Genzyme MSD contingent consideration (European Vaccines business) Other Total (a) Balance at January 1, 2020 156 385 259 800 Payments made (37) (78) (2) (117) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) 11 37 (72) (24) Other movements — — (2) (2) Currency translation differences 1 (4) 2 (1) Balance at June 30, 2020 131 340 185 656 Of which: • Current portion 243 • Non-current portion 413 (a) As of January 1, 2020, this comprised a non-current portion of €508 million and a current portion of €292 million. (b) Amounts reported within the income statement line item Fair value remeasurement of contingent consideration.

PROVISIONS AND OTHER LIABILIT_2

PROVISIONS AND OTHER LIABILITIES (Tables)	6 Months Ended
PROVISIONS AND OTHER LIABILITIES (Tables)	Jun. 30, 2020
Subclassifications of assets, liabilities and equities [abstract]
Summary of Non Current Provisions and Other Non-current Liabilities	The line item Non-current provisions and other non-current liabilities breaks down as follows: (€ million) June 30, 2020 June 30, 2019 December 31, 2019 Non-current provisions 7,768 7,401 7,353 Other non-current liabilities 2,017 1,698 1,968 Total 9,785 9,099 9,321
Summary of Movements in Non-current Provisions	The table below shows movements in provisions: (€ million) Provisions for pensions & other post-employment benefits Provisions for other long-term benefits Restructuring provisions Other provisions Total Balance at January 1, 2020 3,827 855 600 2,071 7,353 Increases in provisions and other liabilities 144 60 531 (a) 149 884 Provisions utilized (47) (66) (2) (98) (213) Reversals of unutilized provisions (93) — (21) (78) (b) (192) Transfers — (1) (117) (c) (76) (194) Net interest related to employee benefits, and unwinding of discount 29 1 — 5 35 Currency translation differences (24) (2) (3) (22) (51) Actuarial gains and losses on defined-benefit plans 146 — — — 146 Balance at June 30, 2020 3,982 847 988 1,951 7,768 (a) Charges to restructuring provisions relate mainly to headcount adjustment plans in Europe. (b) Amounts charged during the first half of 2020 relate mainly to provisions for products, litigation and other liabilities (c) This movement includes transfers between current and non-current.
Disclosure of Remeasuresment of Net Defined Benefit Liability Asset	Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax): (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Actuarial gains/(losses) on plan assets 308 655 926 Actuarial gains/(losses) on benefit obligations (454) (a) (1,190) (b) (1,301) (a) Includes the effects of (i) the change in the discount rate in the United Kingdom and the United States (-0.50%) and (ii) the change in the inflation rate in the United Kingdom (-0.05%) in the first half of 2020. (b) Includes the effects of changes in discount rates (in a range between -0.65% and -1.00%) and in the United Kingdom inflation rate (+0.05%) in the first half of 2019.
Other Non-current Liabilities	Other non-current liabilities comprise the following : (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Non-current liabilities related to income taxes (a) 1,712 1,452 1,666 Other non-current liabilities 305 246 302 Total 2,017 1,698 1,968 (a) Non-current liabilities related to income taxes include uncertainties over income tax treatments amounting to €1,064 million as of June 30, 2020, €812 million as of June 30, 2019, and €1,031 million as of December 31, 2019.

Other Operating Income And Ex_2

Other Operating Income And Expenses (Tables)	6 Months Ended
Other Operating Income And Expenses (Tables)	Jun. 30, 2020
Analysis of income and expense [abstract]
Other Operating Expenses	Other operating expenses for the first half of 2020 included €525 million of expenses relating to the alliance with Regeneron (versus €241 million in the first half of 2019), as shown in the table below. (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Income & expense related to (profit)/loss sharing of the Antibodies Alliance (341) (16) (253) Additional share of profit paid by Regeneron related to development costs 35 — 21 Regeneron commercial operating expenses reimbursement (176) (218) (449) Total: Antibody Alliance (482) (234) (681) Immuno-Oncology Alliance 44 30 62 Other (mainly Zaltrap®) (8) (7) (14) Other operating income/(expenses), net, related to Regeneron Alliance (446) (211) (633) of which amount presented in Other operating income 79 30 82

Restructuring Costs And Simil_2

Restructuring Costs And Similar Items (Tables)	6 Months Ended
Restructuring Costs And Similar Items (Tables)	Jun. 30, 2020
Analysis of income and expense [abstract]
Summary of Restructuring Costs and Similar Items	Restructuring costs and similar items comprise the following: (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Employee-related expenses 642 667 791 Expenses related to property, plant and equipment and to inventories 62 39 106 Compensation for early termination of contracts (other than contracts of employment) 11 3 49 Decontamination costs — 1 27 Other restructuring costs 43 37 89 Total 758 747 1,062

Financial Expenses and Income (

Financial Expenses and Income (Tables)	6 Months Ended
Financial Expenses and Income (Tables)	Jun. 30, 2020
Analysis of income and expense [abstract]
Summary of Analysis of Financial Income and Expenses	An analysis of financial expenses and income is set forth below: (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Cost of debt (a) (166) (171) (318) Interest income (b) 66 82 146 Cost of net debt (100) (89) (172) Non-operating foreign exchange gains/(losses) 2 3 1 Unwinding of discounting of provisions (c) (6) (12) (25) Net interest cost related to employee benefits (32) (45) (87) Net interest expense on lease liabilities (d) (19) (20) (39) Other (12) 13 19 Net financial income/(expenses) (167) (150) (303) comprising: Financial expenses (198) (244) (444) Financial income 31 94 141 (a) Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: €58 million in the first half of 2020, €83 million in the first half of 2019, and €187 million over the whole of 2019. (b) Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: €37 million in the first half of 2020, €27 million in the first half of 2019, and €55 million over the whole of 2019. (c) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.). (d) Impact of IFRS 16 (Leases), see Note A.2.1. to the 2019 consolidated financial statements.

Income Tax Expense (Tables)

Income Tax Expense (Tables)	6 Months Ended
Income Tax Expense (Tables)	Jun. 30, 2020
Income Taxes [Abstract]
Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes	The table below shows the allocation of income tax expense between current and deferred taxes: (€ million) June 30, 2020 (6 months) June 30, 2019 (6 months) December 31, 2019 (12 months) Current taxes (1,127) (828) (1,892) Deferred taxes 133 815 1,753 Total (994) (13) (139) Income before tax and investments accounted for using the equity method 9,941 962 2,822
Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate	The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows: (as a percentage) June 30, 2020 (6 months) (a) June 30, 2019 (6 months) (a) December 31, 2019 (12 months) Standard tax rate applicable in France 32.0 34.4 34.4 Difference between the standard French tax rate and the rates applicable to Sanofi (b) (20.2) (13.7) (22.9) Impact of commitments arising from business divestitures — (12.1) (6.2) Revisions to tax exposures and settlements of tax disputes 0.2 4.5 4.8 Fair value remeasurement of contingent consideration liabilities (0.1) (3.0) (2.6) Other (c) (1.9) (8.8) (2.6) Effective tax rate 10.0 1.3 4.9 (a) Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.). (b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. For 2020, the percentage is impacted by the difference between the normal French tax rate and the tax rate applicable to the sale of Regeneron shares. (c) For 2019, the percentage on the “Other” line is impacted by the reduction in Income before tax and investments accounted for using the equity method .

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
Segment Information (Tables)	Jun. 30, 2020
Operating Segments [Abstract]
Summary of Net Sales by Segment and Geographical Area	The table below sets forth net sales for the six months ended June 30, 2020 and June 30, 2019: (€ million) Europe United States Other countries June 30, 2020 Europe United States Other countries June 30, 2019 Pharmaceuticals 3,347 4,806 4,867 13,020 3,393 4,193 5,132 12,718 General Medicines 2,232 1,458 3,928 7,618 2,421 1,647 4,336 8,404 of which Lantus ® 281 474 662 1,417 306 568 658 1,532 Toujeo ® 188 143 165 496 167 139 125 431 Praluent ® 56 68 22 146 63 44 15 122 Multaq ® 12 135 7 154 20 135 6 161 Lovenox ® 298 15 317 630 385 18 287 690 Plavix ® 67 5 437 509 70 — 696 766 Generics 57 75 362 494 66 79 391 536 Specialty Care 1,115 3,348 939 5,402 972 2,546 796 4,314 of which Aubagio ® 231 775 62 1,068 204 645 54 903 Cerezyme ® 125 90 153 368 128 88 147 363 Myozyme/Lumizyme ® 193 178 101 472 195 162 97 454 Fabrazyme ® 98 206 109 413 90 199 107 396 Eloctate ® — 234 96 330 — 272 73 345 Jevtana ® 92 123 56 271 87 101 49 237 Dupixent ® 174 1,310 150 1,634 83 669 73 825 Consumer Healthcare 717 583 1,024 2,324 741 599 1,067 2,407 of which Allergy, Cough and Cold 177 214 249 640 184 187 246 617 Pain 271 98 266 635 275 93 273 641 Digestive 167 38 221 426 175 103 260 538 Nutritionals 62 23 223 308 67 19 214 300 Vaccines 281 491 1,064 1,836 317 609 968 1,894 of which Polio/Pertussis/Hib vaccines 162 183 714 1,059 157 192 639 988 Influenza vaccines 5 13 161 179 2 4 111 117 Total net sales 4,345 5,880 6,955 17,180 4,451 5,401 7,167 17,019
Schedule of Segment Results	Segment results are shown in the table below: June 30, 2020 (6 months) (€ million) Pharmaceuticals Consumer Healthcare Vaccines Other Total Net sales 13,020 2,324 1,836 — 17,180 Other revenues 70 30 474 — 574 Cost of sales (3,427) (770) (1,184) (126) (5,507) Research and development expenses (2,143) (61) (324) (164) (2,692) Selling and general expenses (2,472) (760) (386) (989) (4,607) Other operating income and expenses (150) 21 4 (130) (255) Share of profit/(loss) from investments accounted for using the equity method (a) 4 7 — — 11 Net income attributable to non-controlling interests (17) (4) — — (21) Business operating income 4,885 787 420 (1,409) 4,683 (a) “Business operating income” no longer includes Sanofi’s equity-accounted share of Regeneron’s net profits (see definition above, and Note B.1.). June 30, 2019 (6 months) (€ million) Pharmaceuticals Consumer Healthcare Vaccines Other Total Net sales 12,718 2,407 1,894 — 17,019 Other revenues 103 27 544 — 674 Cost of sales (3,239) (783) (1,255) (105) (5,382) Research and development expenses (2,423) (71) (295) (183) (2,972) Selling and general expenses (2,679) (760) (374) (1,022) (4,835) Other operating income and expenses (228) 105 (6) (64) (193) Share of profit/(loss) from investments accounted for using the equity method (a) 4 6 — — 10 Net income attributable to non-controlling interests (12) (3) — — (15) Business operating income (b) 4,244 928 508 (1,374) 4,306 (a) “Business operating income” no longer includes Sanofi’s equity-accounted share of Regeneron’s net profits (see definition above, and Note B.1.). (b) Restated to exclude (i) Sanofi’s share of net profits from the investment in Regeneron (see above); and to include (i) the effects of IFRS 16 and (ii) the effect of certain expenses and income being presented differently for segment reporting purposes to align on Sanofi’s new 2020 management reporting structure. December 31, 2019 (12 months) (€ million) Pharmaceuticals Consumer Healthcare Vaccines Other Total Net sales 25,700 4,695 5,731 — 36,126 Other revenues 173 57 1,275 — 1,505 Cost of sales (6,750) (1,599) (3,372) (252) (11,973) Research and development expenses (4,850) (149) (639) (380) (6,018) Selling and general expenses (5,442) (1,529) (823) (2,089) (9,883) Other operating income and expenses (625) 193 — 50 (382) Share of profit/(loss) from investments accounted for using the equity method (a) 5 (5) 9 — 9 Net income attributable to non-controlling interests (29) (6) — — (35) Business operating income (b) 8,182 1,657 2,181 (2,671) 9,349
Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method	The table below, presented in compliance with IFRS 8, shows a reconciliation between “Business operating income” and Income before tax and investments accounted for using the equity method: (€ million) June 30, 2020 (6 months) June 30, 2019 (f) (6 months) December 31, 2019 (f) (12 months) Business operating income 4,683 4,306 9,349 Share of profit/(loss) from investments accounted for using the equity method (a)/(b) (11) (10) (9) Net income attributable to non-controlling interests (c) 21 15 35 Amortization and impairment of intangible assets (1,206) (2,956) (5,750) Fair value remeasurement of contingent consideration 54 190 238 Expenses arising from the impact of acquisitions on inventories (36) (3) (3) Restructuring costs and similar items (758) (747) (1,062) Other gains and losses, and litigation (d) 136 317 327 Gain on sale of Regeneron shares on May 29, 2020 (e) 7,225 — — Operating income 10,108 1,112 3,125 Financial expenses (198) (244) (444) Financial income 31 94 141 Income before tax and investments accounted for using the equity method 9,941 962 2,822 (a) Excludes (i) restructuring costs and (ii) expenses arising from the impact of acquisitions on investments accounted for using the equity method. (b) Following the transaction of May 29, 2020, “Business operating income” no longer includes Sanofi’s equity-accounted share of Regeneron’s net profits (see Note B.1.). Consequently, this line does not include Sanofi’s share of net profits from the investment in Regeneron up to and including that date. (c) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (d) For the six months ended June 30, 2020, this line mainly comprises the gain on the sale of operations related to the Seprafilm product to Baxter. (e) This line includes the gain on the sale of (i) 13 million shares of Regeneron common stock in the registered public offering and (ii) the 9.8 million shares repurchased by Regeneron, but does not include the gain arising from the remeasurement of the 400,000 retained shares at market value of May 29, 2020. (f) Business operating income as presented in the 2019 financial statements has been restated to exclude (i) Sanofi’s share of net profits from the investment in Regeneron, amounting to €159 million in the six months ended June 30, 2019 and €411 million in the year ended December 31, 2019 (see above); and to include (i) the effects of IFRS 16 and (ii) the effect of certain expenses and income being presented differently for segment reporting purposes to align on Sanofi’s new 2020 management reporting structure.
Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment	Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period. June 30, 2020 (€ million) Pharmaceuticals Consumer Healthcare Vaccines Total Investments accounted for using the equity method 149 3 44 196 Acquisitions of property, plant and equipment 294 27 181 502 Acquisitions of other intangible assets 153 6 21 180 June 30, 2019 (€ million) Pharmaceuticals Consumer Healthcare Vaccines Total Investments accounted for using the equity method (a) 327 20 32 379 Acquisitions of property, plant and equipment (b) 383 28 243 654 Acquisitions of other intangible assets 124 7 56 187 (a) This line has been restated to eliminate Sanofi’s equity investment in Regeneron (see Note B.20.) . (b) Includes the effect of restatements needed to align on Sanofi’s new 2020 management reporting structure. December 31, 2019 (€ million) Pharmaceuticals Consumer Healthcare Vaccines Total Investments accounted for using the equity method (a) 205 4 40 249 Acquisitions of property, plant and equipment (b) 773 88 462 1,323 Acquisitions of other intangible assets 321 51 121 493 (a) This line has been restated to eliminate Sanofi’s equity investment in Regeneron (see Note B.20.) . (b) Includes the effect of restatements needed to align on Sanofi’s new 2020 management reporting structure.
Summary of Geographical Information on Net Sales and Non-Current Assets	In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16. June 30, 2020 (€ million) Total Europe of which France North of which United States Other countries Net sales 17,180 4,345 1,061 6,151 5,880 6,684 Non-current assets: • property, plant and equipment 9,368 5,683 3,067 2,756 2,153 929 • goodwill 45,254 — — — — — • other intangible assets 17,021 6,544 — 8,838 — 1,639 June 30, 2019 (€ million) Total Europe of which France North of which United States Other countries Net sales 17,019 4,351 1,099 5,685 5,401 6,983 Non-current assets: • property, plant and equipment 9,606 5,781 3,120 2,791 2,250 1,034 • goodwill 44,418 — — — — — • other intangible assets 19,098 7,439 — 9,485 — 2,174 December 31, 2019 (€ million) Total Europe of which France North of which United States Other countries Net sales 36,126 8,852 2,261 13,370 12,756 13,904 Non-current assets: • property, plant and equipment 9,717 5,824 3,141 2,862 2,264 1,031 • goodwill 44,519 — — — — — • other intangible assets 16,572 6,941 — 7,825 — 1,806

Basis of Preparation of the H_4

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies - Additional Information (Details) € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)
Corporate Information And Statement Of IFRS Compliance [Abstract]
Hyperinflation expense	€ 16

Changes in the Scope of Conso_3

Changes in the Scope of Consolidation Due to Acquisitions and Divestments - Additional Information (Details) $ / shares in Units, € in Millions, $ in Millions	May 29, 2020EUR (€)shares	May 29, 2020USD ($)shares	Jun. 30, 2020EUR (€)shares		Jun. 30, 2019EUR (€)		Dec. 31, 2019EUR (€)		May 29, 2020$ / shares	Jan. 23, 2020EUR (€)	Jan. 23, 2020USD ($)$ / shares
Disclosure of detailed information about business combination [line items]
Investments accounted for using the equity method			€ 196				€ 3,591
Gain on Regeneron investment arising from transaction of May 29, 2020			7,382		€ 0		0
Regeneron
Disclosure of detailed information about business combination [line items]
Sale of stock, number of shares issued in transaction (in shares) \| shares	22,800,000	22,800,000
Proceeds from sale of Regeneron shares on May 29, 2020, net of transaction-related costs	€ 10,512		10,512	[1]	0	[1]	0	[1]
Investments accounted for using the equity method	3,668
Gain on Regeneron investment arising from transaction of May 29, 2020	7,382
Sale of stock, transaction costs	64
Gains (losses) on remeasuring available-for-sale financial assets, net of tax	157
Quoted stock market price per share ($ per share) \| $ / shares									$ 612.81
Tax expense on disposal of investment	512
Proceeds from sales of investments accounted for using equity method, before transaction costs	10,575
Proceeds from sale of Regeneron shares on May 29, 2020, net of transaction-related costs	10,512		10,512	[1]	€ 0	[1]	€ 0	[1]
Fair value through other comprehensive income	€ 221		€ 152
Non-current financial assets, number of shares (in shares) \| shares	400,000		279,766
Regeneron \| Two thousand eighteen letter agreement
Disclosure of detailed information about business combination [line items]
Regeneron ordinary shares sold to regeneron \| shares			779,320
Aggregate number of regeneron shares that could be sold for cemiplimab and dupilumab funding costs (in shares) \| shares			1,400,000
Regeneron \| Reserve of exchange differences on translation
Disclosure of detailed information about business combination [line items]
Gain on Regeneron investment arising from transaction of May 29, 2020	€ 318
Public Offering \| Regeneron
Disclosure of detailed information about business combination [line items]
Sale of stock, number of shares issued in transaction (in shares) \| shares	13,000,000	13,000,000
Sale of stock (in USD per share) \| $ / shares									515
Proceeds from sales of investments accounted for using equity method, before transaction costs \| $		$ 6,700
Sale of stock (in USD per share) \| $ / shares									515
Repurchase From The Counterpart \| Regeneron \| Regeneron Pharmaceuticals, Inc
Disclosure of detailed information about business combination [line items]
Sale of stock (in USD per share) \| $ / shares									509.85
Number of shares issued in transaction (in shares) \| shares	9,800,000
Number of shares issued in transaction (in shares) \| shares	9,800,000
Proceeds from sales of investments accounted for using equity method, before transaction costs \| $		$ 5,000
Sale of stock (in USD per share) \| $ / shares									$ 509.85
Synthorx
Disclosure of detailed information about business combination [line items]
Purchase price (in USD per share) \| $ / shares											$ 68
Purchase price										€ 2,246	$ 2,500
Goodwill recognised as of acquisition date										€ 901
Negative contribution to consolidated net income			€ (70)
Purchase of interests in investments accounted for using equity method			€ (2,246)

[1]	The amount recognized as of June 30, 2020 does not include the effects of the tax arising on the transaction, which will be paid in the second half of the year and is estimated at approximately €400 million.

Changes in the Scope of Conso_4

Changes in the Scope of Consolidation Due to Acquisitions and Divestments - Summary of Purchase Price Allocation (Details) - Jan. 23, 2020 - Synthorx € in Millions, $ in Billions	USD ($)	EUR (€)
Disclosure of detailed information about business combination [line items]
Intangible assets other than goodwill		€ 1,549
Other current and non-current assets and liabilities		41
Net deferred tax position		(245)
Net assets of Synthorx		1,345
Goodwill recognised as of acquisition date		901
Purchase price	$ 2.5	€ 2,246

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details) - EUR (€) € in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	€ 389	€ 1,261
Capitalized interest	6	14
Pharmaceuticals
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	234	846
Pharmaceuticals \| Industrial facilities
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	196	682
Pharmaceuticals \| Research sites
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	37	87
Pharmaceuticals \| Other
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	1	77
Vaccines
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	128	405
Consumer Healthcare
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	€ 27	€ 10

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)
Disclosure of detailed information about property, plant and equipment [abstract]
Firm orders of property, plant and equipment	€ 535

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details) € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	€ 16,572
Other intangible assets, Ending balance	17,021
Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	71,381
Changes in scope of consolidation (a)	1,549
Acquisitions and other increases	218
Disposals and other decreases	(135)
Currency translation differences	(157)
Transfers	(2)
Other intangible assets, Ending balance	72,854
Accumulated depreciation, amortisation and impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	(54,809)
Amortization expense	(957)
Impairment losses, net of reversals	(323)
Disposals and other decreases	135
Currency translation differences	118
Transfers	3
Other intangible assets, Ending balance	(55,833)
Acquired R&D
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	2,334
Other intangible assets, Ending balance	3,485
Acquired R&D \| Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	5,730
Changes in scope of consolidation (a)	1,417
Acquisitions and other increases	115
Disposals and other decreases	(17)
Currency translation differences	(28)
Transfers	(52)
Other intangible assets, Ending balance	7,165
Acquired R&D \| Accumulated depreciation, amortisation and impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	(3,396)
Amortization expense	0
Impairment losses, net of reversals	(321)
Disposals and other decreases	17
Currency translation differences	2
Transfers	18
Other intangible assets, Ending balance	(3,680)
Products, trademarks and other rights
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	13,639
Other intangible assets, Ending balance	12,937
Products, trademarks and other rights \| Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	63,953
Changes in scope of consolidation (a)	132
Acquisitions and other increases	38
Disposals and other decreases	(106)
Currency translation differences	(118)
Transfers	52
Other intangible assets, Ending balance	63,951
Products, trademarks and other rights \| Accumulated depreciation, amortisation and impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	(50,314)
Amortization expense	(895)
Impairment losses, net of reversals	(2)
Disposals and other decreases	105
Currency translation differences	107
Transfers	(15)
Other intangible assets, Ending balance	(51,014)
Software
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	599
Other intangible assets, Ending balance	599
Software \| Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	1,698
Changes in scope of consolidation (a)	0
Acquisitions and other increases	65
Disposals and other decreases	(12)
Currency translation differences	(11)
Transfers	(2)
Other intangible assets, Ending balance	1,738
Software \| Accumulated depreciation, amortisation and impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, Beginning balance	(1,099)
Amortization expense	(62)
Impairment losses, net of reversals	0
Disposals and other decreases	13
Currency translation differences	9
Transfers	0
Other intangible assets, Ending balance	€ (1,139)

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Additional Information (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2020	Jan. 23, 2020	Dec. 31, 2019
Disclosure of reconciliation of changes in goodwill [line items]
goodwill	€ 45,254		€ 44,519
Synthorx
Disclosure of reconciliation of changes in goodwill [line items]
Identifiable intangible assets recognised as of acquisition date		€ 1,549
Goodwill recognised as of acquisition date		€ 901
Marketed products
Disclosure of reconciliation of changes in goodwill [line items]
Identifiable intangible assets recognised as of acquisition date	€ 12,500		13,300
Weighted average amortization period	10 years
Trademarks
Disclosure of reconciliation of changes in goodwill [line items]
Identifiable intangible assets recognised as of acquisition date	€ 100		€ 100
Weighted average amortization period	12 years
Intangible assets excluding software
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions of other intangible assets	€ 153

Impairment of Intangible Asse_2

Impairment of Intangible Assets - Additional Information (Details) € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)
Other intangible assets
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment loss on intangible assets other than goodwill excluding software	€ 323

Investments Accounted for Usi_3

Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details) € in Millions, $ in Millions	May 29, 2020shares	Feb. 29, 2020USD ($)	Jun. 30, 2020EUR (€)shares	Dec. 31, 2019EUR (€)
Disclosure of transactions between related parties [Line Items]
Investments in subsidiaries, joint ventures and associates			€ 196	€ 3,591
Infraserv GmbH & Co. Höchst KG
Disclosure of transactions between related parties [Line Items]
Proportion of voting rights held in joint venture			31.20%
Investments in joint ventures			€ 62	70
Other investments
Disclosure of transactions between related parties [Line Items]
Proportion of voting rights held in joint venture			0.00%
Investments in joint ventures			€ 134	142
Regeneron Pharmaceuticals, Inc
Disclosure of transactions between related parties [Line Items]
% interest
Investments in associates			€ 0	3,342
Entities and companies managed by Bristol-Myers Squibb
Disclosure of transactions between related parties [Line Items]
% interest			100.00%
Investments in associates			€ 0	€ 37
Equity interest		50.10%
Purchase of interests in investments accounted for using equity method \| $		$ 12
Regeneron
Disclosure of transactions between related parties [Line Items]
Sale of stock, number of shares issued in transaction (in shares) \| shares	22,800,000
Non-current financial assets, number of shares (in shares) \| shares	400,000		279,766

Investments Accounted for Usi_4

Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details) - Associates and joint ventures - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure of transactions between related parties [Line Items]
Sales	€ 52	€ 16	€ 24
Royalties and other income	65	153	270
Accounts receivable and other receivables	7	160	151
Purchases and other expenses (including research expenses)	605	608	1,334
Accounts payable and other payables	€ 5	€ 373	€ 342

Other Non-Current Assets - Summ

Other Non-Current Assets - Summary of Other Non-current Assets (Details) - EUR (€) € in Millions	Jun. 30, 2020	Dec. 31, 2019
Disclosure Of Other Non Current Assets [Line Items]
Other financial assets at fair value through profit or loss	€ 812	€ 892
Pre-funded pension obligations	156	155
Long-term prepaid expenses	103	115
Long-term loans and advances and other non-current receivables	616	685
Derivative financial instruments	33	37
Total	3,031	2,667
Trading equity securities
Disclosure Of Other Non Current Assets [Line Items]
Fair value through other comprehensive income	872	380
Debt securities
Disclosure Of Other Non Current Assets [Line Items]
Fair value through other comprehensive income	€ 439	€ 403

Other Non-Current Assets - Addi

Other Non-Current Assets - Additional Information (Details) - EUR (€) € in Millions	May 29, 2020	Jun. 30, 2020	Dec. 31, 2019
Disclosure Of Other Non Current Assets [Line Items]
Investments accounted for using the equity method		€ 196	€ 3,591
Other non-current assets		3,031	2,667
Regeneron
Disclosure Of Other Non Current Assets [Line Items]
Fair value through other comprehensive income	€ 221	152
Sale of stock, number of shares issued in transaction (in shares)	22,800,000
Investments accounted for using the equity method	€ 3,668
Trading equity securities
Disclosure Of Other Non Current Assets [Line Items]
Fair value through other comprehensive income		872	€ 380
Trading equity securities \| Associates
Disclosure Of Other Non Current Assets [Line Items]
Fair value through other comprehensive income		€ 360

Accounts Receivable - Summary o

Accounts Receivable - Summary of Accounts Receivable (Details) - EUR (€) € in Millions	Jun. 30, 2020	Dec. 31, 2019
Disclosure of Accounts Receivable [Line Items]
Accounts receivable	€ 7,203	€ 7,937
Gross value
Disclosure of Accounts Receivable [Line Items]
Accounts receivable	7,379	8,090
Allowances
Disclosure of Accounts Receivable [Line Items]
Accounts receivable	€ (176)	€ (153)

Accounts Receivable - Additiona

Accounts Receivable - Additional Information (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Subclassifications of assets, liabilities and equities [abstract]
Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables	€ 40	€ (2)
Derecognized receivables	€ 322		€ 214

Accounts Receivable - Summary_2

Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details) - EUR (€) € in Millions	Jun. 30, 2020	Dec. 31, 2019
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	€ 633	€ 642
Less than 1 Month
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	210	269
1 to 3 Months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	208	171
3 to 6 Months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	81	61
6 to 12 Months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	29	36
Greater than 12 Months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	€ 105	€ 105

Consolidated Shareholders' Eq_3

Consolidated Shareholders' Equity - Additional Information (Details) - EUR (€)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Jun. 26, 2020	Feb. 05, 2020
Disclosure of classes of share capital [Line Items]
Share capital	€ 2,512,384,148
Number of shares (in shares)	1,256,192,074
Par value per share (in euros per share)	€ 2
Expense recognized through equity	€ 0	€ 3,000,000
Number of stock option not taken for computing diluted earning per share (in shares)	700,000	1,100,000	800,000
Share capital	€ 2,512,384,148
Number of shares (in shares)	1,256,192,074
Par value per share (in euros per share)	€ 2
Expense recognized	€ 0	€ 3,000,000
Number of stock option not taken for computing diluted earning per share (in shares)	700,000	1,100,000	800,000
Other comprehensive income that will be reclassified to profit or loss, net of tax	€ (902,000,000)	€ 440,000,000	€ 813,000,000
Share capital \| Sanofi
Disclosure of classes of share capital [Line Items]
Capital increase by exercise of stock subscription options (in shares)	679,707
Capital increase by issuance of restricted shares (in shares)	3,073,755
April 28, 2020
Disclosure of classes of share capital [Line Items]
Period of share repurchase program	18 months
Period of share repurchase program	18 months
April 30, 2019
Disclosure of classes of share capital [Line Items]
Period of share repurchase program	18 months
Period of share repurchase program	18 months
Share repurchase 2018 program
Disclosure of classes of share capital [Line Items]
Impact on shareholders' equity	€ 361,000,000
Number of shares (in shares)	3,982,939
Value	€ 361,000,000
Employees share ownership plan
Disclosure of classes of share capital [Line Items]
Expense recognized through equity	52,000,000
Subscription price (in euros per share)					€ 70.67
Number of shares subscribed (in shares)				2,467,101
Number of shares issued immediately as employer's contribution (in shares)				123,615
Expense recognized	€ 52,000,000

Consolidated Shareholders' Eq_4

Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details) - shares shares in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Jan. 01, 2019
Share Capital, Reserves And Other Equity Interest [Abstract]
Number of shares (in shares)	2,590	20	20	1,940
% of share capital for the period	0.207%	0.002%	0.002%	0.156%

Consolidated Shareholders' Eq_5

Consolidated Shareholders' Equity - Principal Characteristics of Restricted Share Plans (Details) - Restricted share plan 2020 € / shares in Units, € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)shares€ / shares
Disclosure of classes of share capital [Line Items]
Service period	3 years
Total number of shares awarded (in shares) \| shares	3,340,501
Fair value per share awarded (in euros per share) \| € / shares	€ 82.36
Fair value of plan at the date of grant \| €	€ 275

Consolidated Shareholders' Eq_6

Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disclosure of classes of share capital [Line Items]
Total expense for restricted share plans	€ 0	€ 3
Restricted shares
Disclosure of classes of share capital [Line Items]
Total expense for restricted share plans	€ 113	€ 128
Number of shares not yet fully vested (in shares)	10,900,815	11,251,318
Restricted share plan 2020
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	3,340,501	0
Restricted share plan 2019
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	3,545,507	3,797,582
Restricted share plan 2018
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	4,014,807	4,252,339
Restricted share plan 2017
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	0	3,201,397

Consolidated Shareholders' Eq_7

Consolidated Shareholders' Equity - Summary of Expense Recognized Through Equity for Stock Option Plans (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share Capital, Reserves And Other Equity Interest [Abstract]
Expense recognized through equity	€ 0	€ 3

Consolidated Shareholders' Eq_8

Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details) - Stock Option Plan	6 Months Ended
	Jun. 30, 2020shares€ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Number of options (in shares) \| shares	2,801,838
Exercisable, Number of options (in shares) \| shares	2,033,998
From €50.00 to €60.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Number of options (in shares) \| shares	277,506
Weighted average residual life (years)	1 year 3 months 25 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in EUR per share)	€ 54.28
Exercisable, Number of options (in shares) \| shares	277,506
Weighted average exercise price per share, Options exercisable (in EUR per share)	€ 54.28
From €60.00 to €70.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Number of options (in shares) \| shares	220,000
Weighted average residual life (years)	7 years 10 months 6 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in EUR per share)	€ 65.84
Exercisable, Number of options (in shares) \| shares	0
Weighted average exercise price per share, Options exercisable (in EUR per share)	€ 0
From €70.00 to €80.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Number of options (in shares) \| shares	1,591,528
Weighted average residual life (years)	4 years 7 months 6 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in EUR per share)	€ 74.11
Exercisable, Number of options (in shares) \| shares	1,371,528
Weighted average exercise price per share, Options exercisable (in EUR per share)	€ 73.69
From €80.00 to €90.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Number of options (in shares) \| shares	712,804
Weighted average residual life (years)	5 years 10 months 6 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in EUR per share)	€ 89.19
Exercisable, Number of options (in shares) \| shares	384,964
Weighted average exercise price per share, Options exercisable (in EUR per share)	€ 89.38
Bottom of range \| From €50.00 to €60.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	50
Bottom of range \| From €60.00 to €70.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	60
Bottom of range \| From €70.00 to €80.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	70
Bottom of range \| From €80.00 to €90.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	80
Top of range \| From €50.00 to €60.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	60
Top of range \| From €60.00 to €70.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	70
Top of range \| From €70.00 to €80.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	80
Top of range \| From €80.00 to €90.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	€ 90

Consolidated Shareholders' Eq_9

Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details) - shares shares in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Share Capital, Reserves And Other Equity Interest [Abstract]
Average number of shares outstanding (in shares)	1,251.7	1,247.2	1,249.9
Adjustment for stock options with dilutive effect (in shares)	0.4	1	0.8
Adjustment for restricted shares (in shares)	6.1	6.5	6.4
Average number of shares used to compute diluted earnings per share (in shares)	1,258.2	1,254.7	1,257.1

Consolidated Shareholders' E_10

Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure of analysis of other comprehensive income by item [Line Items]
Items not subsequently reclassifiable to profit or loss	€ 64	€ (384)	€ (163)
Items subsequently reclassifiable to profit or loss	(902)	440	813
Items subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [Line Items]
Items subsequently reclassifiable to profit or loss	1	20	27
Accumulated other comprehensive income \| Items not subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [Line Items]
Actuarial gains/(losses) excluding investments accounted for using the equity method	(146)	(535)	(377)
Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes	0	0	(5)
Tax effects	(19)	155	161
Items not subsequently reclassifiable to profit or loss	64	(384)	(163)
Accumulated other comprehensive income \| Items not subsequently reclassifiable to profit or loss \| Equity instruments included in financial assets
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)	312	19	26
Change in fair value (investments accounted for using the equity method, net of taxes)	(13)	15	80
Tax effects	(70)	(38)	(48)
Change in fair value (excluding investments accounted for using the equity method)	312	19	26
Accumulated other comprehensive income \| Items not subsequently reclassifiable to profit or loss \| Equity instruments included in financial assets \| Dexcom
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)	53
Change in fair value (excluding investments accounted for using the equity method)	53
Accumulated other comprehensive income \| Items subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)	29	(15)	(13)
Change in fair value (investments accounted for using the equity method, net of taxes)	0	0	0
Tax effects	(9)	4	4
Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)	(590)	462	850
Currency translation differences (investments accounted for using the equity method)	24	23	64
Hedges of net investments in foreign operations	(60)	(75)	(163)
Tax effects	19	18	48
Items subsequently reclassifiable to profit or loss	(902)	440	813
Accumulated other comprehensive income \| Items subsequently reclassifiable to profit or loss \| Debt instruments
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)	4	28	28
Change in fair value (investments accounted for using the equity method, net of taxes)	0	0	0
Tax effects	(1)	(5)	(5)
Accumulated other comprehensive income \| Items subsequently reclassifiable to profit or loss \| Regeneron
Disclosure of analysis of other comprehensive income by item [Line Items]
Currency translation differences (investments accounted for using the equity method)	€ (318)	€ 0	€ 0

Debt, Cash and Cash Equivalen_3

Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details) - EUR (€) € in Millions	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Financial Instruments [Abstract]
Long-term debt	€ 20,404	€ 20,131
Short-term debt and current portion of long-term debt	3,329	4,554
Interest rate and currency derivatives used to manage debt	(173)	(117)
Total debt	23,560	24,568
Cash and cash equivalents	(15,969)	(9,427)	€ (6,742)	€ (6,925)
Interest rate and currency derivatives used to manage cash and cash equivalents	89	(34)
Net debt	7,680	15,107
Current and non-current lease liabilities	€ 1,195	€ 1,248

Debt, Cash and Cash Equivalen_4

Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details) - EUR (€) € in Millions	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt	€ 20,404	€ 20,131
Short-term debt and current portion of long-term debt	3,329	4,554
Interest rate and currency derivatives used to manage debt	(173)	(117)
Total debt	23,560	24,568
Cash and cash equivalents	(15,969)	(9,427)	€ (6,742)	€ (6,925)
Interest rate and currency derivatives used to manage cash and cash equivalents	89	(34)
Net debt	7,680	15,107
Current and non-current lease liabilities	1,195	1,248
Amortized cost
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt	77
Short-term debt and current portion of long-term debt	2
Interest rate and currency derivatives used to manage debt	0
Total debt	79
Cash and cash equivalents	0
Interest rate and currency derivatives used to manage cash and cash equivalents	0
Net debt	79
Adjustment to debt measured at fair value
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt	(53)
Short-term debt and current portion of long-term debt	(2)
Interest rate and currency derivatives used to manage debt	29
Total debt	(26)
Cash and cash equivalents	0
Interest rate and currency derivatives used to manage cash and cash equivalents	0
Net debt	(26)
Value on redemption
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt	20,428	20,180
Short-term debt and current portion of long-term debt	3,329	4,553
Interest rate and currency derivatives used to manage debt	(144)	(86)
Total debt	23,613	24,647
Cash and cash equivalents	(15,969)	(9,427)
Interest rate and currency derivatives used to manage cash and cash equivalents	89	(34)
Net debt	€ 7,733	€ 15,186

Debt, Cash and Cash Equivalen_5

Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details) - EUR (€) € in Millions	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Interest rate and currency derivatives used to manage debt	€ (173)	€ (117)
Total debt	23,560	24,568
Cash and cash equivalents	(15,969)	(9,427)	€ (6,742)	€ (6,925)
Interest rate and currency derivatives used to manage cash and cash equivalents	89	(34)
Net debt	7,680	15,107
Value on redemption
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues	22,230	24,207
Other bank borrowings	1,206	196
Other borrowings	14	25
Bank credit balances	307	305
Interest rate and currency derivatives used to manage debt	(144)	(86)
Total debt	23,613	24,647
Cash and cash equivalents	(15,969)	(9,427)
Interest rate and currency derivatives used to manage cash and cash equivalents	89	(34)
Net debt	7,733	15,186
Value on redemption \| non-current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Cash and cash equivalents	0	0
Interest rate and currency derivatives used to manage cash and cash equivalents	0	(6)
Net debt	20,428	20,175
Value on redemption \| current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Cash and cash equivalents	(15,969)	(9,427)
Interest rate and currency derivatives used to manage cash and cash equivalents	89	(28)
Net debt	(12,695)	(4,989)
Value on redemption \| non-current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues	20,340	20,128
Other bank borrowings	75	40
Other borrowings	13	13
Bank credit balances	0	0
Interest rate and currency derivatives used to manage debt	0	0
Total debt	20,428	20,181
Value on redemption \| current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues	1,890	4,079
Other bank borrowings	1,131	156
Other borrowings	1	12
Bank credit balances	307	305
Interest rate and currency derivatives used to manage debt	(144)	(86)
Total debt	€ 3,185	€ 4,466

Debt, Cash and Cash Equivalen_6

Debt, Cash and Cash Equivalents - Additional Information (Details)	1 Months Ended		6 Months Ended
	Apr. 30, 2020EUR (€)tranche	Mar. 31, 2020EUR (€)tranche	Jun. 30, 2020EUR (€)bond	Jun. 30, 2020USD ($)	Jun. 15, 2020USD ($)	Jun. 04, 2020EUR (€)	Mar. 21, 2020EUR (€)	Jan. 13, 2020EUR (€)
Disclosure of detailed information about borrowings [Line Items]
Notional amount	€ 500,000,000	€ 1,500,000,000
Number of tranches \| tranche	2	2
Number of bond issues redeemed \| bond			5
One Billion Of Fixed Rate Bonds Maturing April Two Thousand Twenty Five
Disclosure of detailed information about borrowings [Line Items]
Notional amount	€ 250,000,000		€ 1,000,000,000
Bonds, interest rate			1.00%	1.00%
One Million Bonds Maturing January Two Thousand Twenty
Disclosure of detailed information about borrowings [Line Items]
Notional amount								€ 1,000,000,000
One Million Bonds Maturing March Two Thousand Twenty
Disclosure of detailed information about borrowings [Line Items]
Notional amount							€ 1,000,000,000
Five Million Bonds Maturing March Two Thousand Twenty
Disclosure of detailed information about borrowings [Line Items]
Notional amount							€ 500,000,000
One Billion Bonds Maturing September Two Thousand Twenty
Disclosure of detailed information about borrowings [Line Items]
Notional amount						€ 1,000,000,000
Five Million Bonds Maturing June Two Thousand Twenty
Disclosure of detailed information about borrowings [Line Items]
Notional amount \| $					$ 500,000,000
Seven Hundred And Fifty Million Of Fixed Rate Bonds Maturing March Two Thousand Twenty Five
Disclosure of detailed information about borrowings [Line Items]
Notional amount		€ 750,000,000
Bonds, interest rate		1.00%
Seven Hundred and Fifty Million Of Fixed Rate Bonds Maturing March Two Thousand Thirty
Disclosure of detailed information about borrowings [Line Items]
Notional amount		€ 750,000,000
Bonds, interest rate		1.50%
One Billion Of Fixed Rate Bonds Maturing April Two Thousand Thirty
Disclosure of detailed information about borrowings [Line Items]
Notional amount	€ 250,000,000		€ 1,000,000,000
Bonds, interest rate			1.50%	1.50%
Syndicated credit facility, expires in 2020
Disclosure of detailed information about borrowings [Line Items]
Credit facilities maximum amount \| $				$ 4,000,000,000
Syndicated credit facility, expires in 2021
Disclosure of detailed information about borrowings [Line Items]
Credit facilities maximum amount \| $				4,000,000,000
Commercial paper program in France
Disclosure of detailed information about borrowings [Line Items]
Commercial paper programs			€ 6,000,000,000
Commercial paper program in USA
Disclosure of detailed information about borrowings [Line Items]
Commercial paper programs \| $				10,000,000,000
Average drawdown \| $				$ 2,600,000,000

Debt, Cash and Cash Equivalen_7

Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details) - EUR (€) € in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure of detailed information about borrowings [Line Items]
Market value	€ 23,560	€ 24,568
At market value
Disclosure of detailed information about borrowings [Line Items]
Market value	9,126	16,370
Value on redemption
Disclosure of detailed information about borrowings [Line Items]
Market value	23,613	24,647
Value on redemption	€ 7,733	€ 15,186

Derivative Financial Instrume_3

Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details) € in Millions	Jun. 30, 2020EUR (€)
Notional amount
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	€ 4,803
Notional amount \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3,251
Notional amount \| Forward currency sales in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,070
Notional amount \| Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	493
Notional amount \| Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	203
Notional amount \| Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	182
Notional amount \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,552
Notional amount \| Forward currency sales in Saudi Riyal
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	158
Notional amount \| Forward currency purchases in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	537
Notional amount \| Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	487
Notional amount \| Forward currency purchased in Canadian Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	68
Notional amount \| Forward currency purchased in Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	46
Notional amount \| Forward Currency Purchased In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	41
Notional amount \| Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales in Saudi Riyal
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency purchases in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency purchased in Canadian Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency purchased in Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward Currency Purchased In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Not eligible for hedge accounting
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	4,803
Notional amount \| Not eligible for hedge accounting \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3,251
Notional amount \| Not eligible for hedge accounting \| Forward currency sales in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,070
Notional amount \| Not eligible for hedge accounting \| Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	493
Notional amount \| Not eligible for hedge accounting \| Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	203
Notional amount \| Not eligible for hedge accounting \| Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	182
Notional amount \| Not eligible for hedge accounting \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,552
Notional amount \| Not eligible for hedge accounting \| Forward currency sales in Saudi Riyal
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	158
Notional amount \| Not eligible for hedge accounting \| Forward currency purchases in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	537
Notional amount \| Not eligible for hedge accounting \| Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	487
Notional amount \| Not eligible for hedge accounting \| Forward currency purchased in Canadian Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	68
Notional amount \| Not eligible for hedge accounting \| Forward currency purchased in Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	46
Notional amount \| Not eligible for hedge accounting \| Forward Currency Purchased In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	41
Fair value
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	7
Fair value \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	15
Fair value \| Forward currency sales in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	7
Fair value \| Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1
Fair value \| Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	4
Fair value \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(8)
Fair value \| Forward currency sales in Saudi Riyal
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Forward currency purchases in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(1)
Fair value \| Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(3)
Fair value \| Forward currency purchased in Canadian Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Forward currency purchased in Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Forward Currency Purchased In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales in Saudi Riyal
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency purchases in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency purchased in Canadian Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency purchased in Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward Currency Purchased In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Not eligible for hedge accounting
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	7
Fair value \| Not eligible for hedge accounting \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	15
Fair value \| Not eligible for hedge accounting \| Forward currency sales in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	7
Fair value \| Not eligible for hedge accounting \| Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1
Fair value \| Not eligible for hedge accounting \| Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Not eligible for hedge accounting \| Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	4
Fair value \| Not eligible for hedge accounting \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(8)
Fair value \| Not eligible for hedge accounting \| Forward currency sales in Saudi Riyal
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Not eligible for hedge accounting \| Forward currency purchases in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(1)
Fair value \| Not eligible for hedge accounting \| Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(3)
Fair value \| Not eligible for hedge accounting \| Forward currency purchased in Canadian Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Not eligible for hedge accounting \| Forward currency purchased in Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Not eligible for hedge accounting \| Forward Currency Purchased In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency sales in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency sales in Saudi Riyal
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency purchases in USD
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency purchased in Canadian Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward currency purchased in Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Of which recognized in equity \| Cash flow hedges \| Forward Currency Purchased In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	€ 0

Derivative Financial Instrume_4

Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details) - Jun. 30, 2020 € in Millions, $ in Millions	EUR (€)	USD ($)
Notional amount
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	€ 16,037
Notional amount \| Forward currency sales
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	5,213
Notional amount \| Forward currency sales in USD \| Bioverativ
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	3,615
Notional amount \| Forward currency sales in USD \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	3,660
Notional amount \| Forward currency sales in Japanese Yen \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	320
Notional amount \| Forward currency sales in Australian dollar \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	225
Notional amount \| Forward currency purchases
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	10,824
Notional amount \| Forward currency purchases in USD \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place \| $		$ 4,000
Notional amount \| Forward currency purchases in USD \| 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	7,056
Notional amount \| Forward currency purchases in Singapore Dollar \| 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	2,443
Notional amount \| Forward currency purchases in Singapore Dollar \| 2020 and 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place \| $		$ 2,000
Notional amount \| Forward Currency Purchased In Japanese yen \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	384
Fair value
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	49
Fair value \| Forward currency sales
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	88
Fair value \| Forward currency sales in USD
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Fair value of forward contracts	88
Fair value \| Forward currency sales in USD \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	87
Fair value \| Forward currency sales in Japanese Yen \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	2
Fair value \| Forward currency sales in Australian dollar \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(1)
Fair value \| Forward currency purchases
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(39)
Fair value \| Forward currency purchases in USD \| 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(19)
Fair value \| Forward currency purchases in Singapore Dollar \| 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(11)
Fair value \| Forward currency purchases in Singapore Dollar \| 2020 and 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(2)
Fair value \| Forward Currency Purchased In Japanese yen \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(4)
Of which recognized in equity \| Forward currency sales in USD
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Fair value of forward contracts	88
Of which recognized in equity \| Forward currency sales in USD \| 2020
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	21
Of which recognized in equity \| Forward currency purchases in Singapore Dollar \| 2020 and 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	€ 12

Derivative Financial Instrume_5

Derivative Financial Instruments - Disclosure of Instruments (Details) € in Millions	Jun. 30, 2020EUR (€)
Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 3,589
Nominal value of interest rate swaps hedge fixed-rate bonds	4,803
Currency and interest rate derivatives	3,589
Notional amount \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	2,544
Currency and interest rate derivatives	2,544
Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	1,045
Nominal value of interest rate swaps hedge fixed-rate bonds	0
Currency and interest rate derivatives	1,045
Notional amount \| 2020
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	890
Currency and interest rate derivatives	890
Notional amount \| 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
Notional amount \| 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	2,642
Currency and interest rate derivatives	2,642
Notional amount \| 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	57
Currency and interest rate derivatives	57
Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	29
Nominal value of interest rate swaps hedge fixed-rate bonds	7
Currency and interest rate derivatives	29
Fair value \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	30
Currency and interest rate derivatives	30
Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(1)
Nominal value of interest rate swaps hedge fixed-rate bonds	0
Currency and interest rate derivatives	(1)
Of which recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(1)
Nominal value of interest rate swaps hedge fixed-rate bonds	0
Currency and interest rate derivatives	€ (1)
pay capitalized Eonia / receive 0.06%
Disclosure of detailed information about financial instruments [line items]
Interest rate	0.06%
pay capitalized Eonia / receive 0.06% \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 2,000
Currency and interest rate derivatives	2,000
pay capitalized Eonia / receive 0.06% \| Notional amount \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	2,000
Currency and interest rate derivatives	2,000
pay capitalized Eonia / receive 0.06% \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% \| Notional amount \| 2020
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% \| Notional amount \| 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% \| Notional amount \| 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	2,000
Currency and interest rate derivatives	2,000
pay capitalized Eonia / receive 0.06% \| Notional amount \| 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	30
Currency and interest rate derivatives	30
pay capitalized Eonia / receive 0.06% \| Fair value \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	30
Currency and interest rate derivatives	30
pay capitalized Eonia / receive 0.06% \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% \| Of which recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	€ 0
pay -0.57% / receive capitalized Eonia
Disclosure of detailed information about financial instruments [line items]
Interest rate	(0.57%)
pay -0.57% / receive capitalized Eonia \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 600
Currency and interest rate derivatives	600
pay -0.57% / receive capitalized Eonia \| Notional amount \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	600
Currency and interest rate derivatives	600
pay -0.57% / receive capitalized Eonia \| Notional amount \| 2020
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia \| Notional amount \| 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia \| Notional amount \| 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	600
Currency and interest rate derivatives	600
pay -0.57% / receive capitalized Eonia \| Notional amount \| 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	3
Currency and interest rate derivatives	3
pay -0.57% / receive capitalized Eonia \| Fair value \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	3
Currency and interest rate derivatives	3
pay -0.57% / receive capitalized Eonia \| Of which recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	€ 0
pay 1.81% / receive 3-month USD Libor
Disclosure of detailed information about financial instruments [line items]
Interest rate	1.81%
pay 1.81% / receive 3-month USD Libor \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 445
Currency and interest rate derivatives	445
pay 1.81% / receive 3-month USD Libor \| Notional amount \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 1.81% / receive 3-month USD Libor \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	445
Currency and interest rate derivatives	445
pay 1.81% / receive 3-month USD Libor \| Notional amount \| 2020
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	445
Currency and interest rate derivatives	445
pay 1.81% / receive 3-month USD Libor \| Notional amount \| 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 1.81% / receive 3-month USD Libor \| Notional amount \| 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 1.81% / receive 3-month USD Libor \| Notional amount \| 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 1.81% / receive 3-month USD Libor \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 1.81% / receive 3-month USD Libor \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(4)
Currency and interest rate derivatives	(4)
pay 1.81% / receive 3-month USD Libor \| Fair value \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 1.81% / receive 3-month USD Libor \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(4)
Currency and interest rate derivatives	(4)
pay 1.81% / receive 3-month USD Libor \| Of which recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(1)
Currency and interest rate derivatives	€ (1)
pay 3-month USD Libor / receive 2.22%
Disclosure of detailed information about financial instruments [line items]
Interest rate	2.22%
pay 3-month USD Libor / receive 2.22% \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 445
Currency and interest rate derivatives	445
pay 3-month USD Libor / receive 2.22% \| Notional amount \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	445
Currency and interest rate derivatives	445
pay 3-month USD Libor / receive 2.22% \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 3-month USD Libor / receive 2.22% \| Notional amount \| 2020
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	445
Currency and interest rate derivatives	445
pay 3-month USD Libor / receive 2.22% \| Notional amount \| 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 3-month USD Libor / receive 2.22% \| Notional amount \| 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 3-month USD Libor / receive 2.22% \| Notional amount \| 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 3-month USD Libor / receive 2.22% \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 3-month USD Libor / receive 2.22% \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	5
Currency and interest rate derivatives	5
pay 3-month USD Libor / receive 2.22% \| Fair value \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	5
Currency and interest rate derivatives	5
pay 3-month USD Libor / receive 2.22% \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
pay 3-month USD Libor / receive 2.22% \| Of which recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	€ 0
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent
Disclosure of detailed information about financial instruments [line items]
Interest rate	1.48%
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 99
Nominal value of interest rate swaps hedge fixed-rate bonds	99
Currency and interest rate derivatives	99
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Notional amount \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	99
Currency and interest rate derivatives	99
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Notional amount \| 2020
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Notional amount \| 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Notional amount \| 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	42
Currency and interest rate derivatives	42
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Notional amount \| 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	57
Currency and interest rate derivatives	57
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(5)
Currency and interest rate derivatives	(5)
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Fair value \| Derivatives Designated as Fair Value Hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(5)
Currency and interest rate derivatives	(5)
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	0
Interest rate swaps receive capitalized Eonia / pay 1.48 Percent \| Of which recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Currency and interest rate derivatives	€ 0

Derivative Financial Instrume_6

Derivative Financial Instruments - Additional Information (Details) - Equity derivatives € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)shares
Disclosure of detailed information about financial instruments [line items]
Shares in derivative instrument (in shares) \| shares	593,712
Financial instruments designated as hedging instruments, at negative fair value \| €	€ 57

Liabilities Related to Busine_3

Liabilities Related to Business Combinations and to Non-Controlling Interest - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance	€ 800
Payments made	(117)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	(24)
Other movements	(2)
Currency translation differences	(1)
Ending balance	656
Current liabilities related to business combinations and to non-controlling interests	243	€ 292
Non-current liabilities related to business combinations and to non-controlling interests	413	€ 508
Bayer contingent consideration arising from the acquisition of Genzyme
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance	156
Payments made	(37)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	11
Other movements	0
Currency translation differences	1
Ending balance	131
MSD contingent consideration (European Vaccines business)
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance	385
Payments made	(78)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	37
Other movements	0
Currency translation differences	(4)
Ending balance	340
Other
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance	259
Payments made	(2)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	(72)
Other movements	(2)
Currency translation differences	2
Ending balance	€ 185

Liabilities Related to Busine_4

Liabilities Related to Business Combinations and to Non-Controlling Interest - Additional Information (Details) € in Millions	6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2020EUR (€)	Dec. 31, 2019EUR (€)
MSD contingent consideration (European Vaccines business)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Disclosure of liabilities related to business combinations and to noncontrolling interests		€ 340	€ 385
Increase in fair value of liability		3.00%
True North Therapeutics
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Disclosure of liabilities related to business combinations and to noncontrolling interests		€ 156	230
Increase in fair value of liability		1.00%
Bayer schering pharma AG
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Disclosure of liabilities related to business combinations and to noncontrolling interests		€ 131	€ 156
Increase in fair value of liability		2.00%
Payment to sale of business period	10 years
Bayer schering pharma AG \| Top of range
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Potentiel payments related to percentage of sales of alemtuzumab \| $	$ 1,250,000,000
Milestone payment \| $	$ 900,000,000

Provisions and Other Liabilit_3

Provisions and Other Liabilities - Summary of Non Current Provisions and Other Non-current Liabilities (Details) - EUR (€) € in Millions	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Subclassifications of assets, liabilities and equities [abstract]
Non-current provisions	€ 7,768	€ 7,353	€ 7,401
Other non-current liabilities	2,017	1,968	1,698
Total	€ 9,785	€ 9,321	€ 9,099

Provisions and Other Liabilit_4

Provisions and Other Liabilities - Summary of Movements in Non-current Provisions (Details) € in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)
Reconciliation of changes in other provisions [abstract]
Beginning balance	€ 7,353
Increases in provisions and other liabilities	884
Provisions utilized	(213)
Reversals of unutilized provisions	(192)
Transfers	(194)
Net interest related to employee benefits, and unwinding of discount	35
Currency translation differences	(51)
Actuarial gains and losses on defined-benefit plans	146
Ending balance	7,768
Provisions for pensions & other post-employment benefits
Reconciliation of changes in other provisions [abstract]
Beginning balance	3,827
Increases in provisions and other liabilities	144
Provisions utilized	(47)
Reversals of unutilized provisions	(93)
Transfers	0
Net interest related to employee benefits, and unwinding of discount	29
Currency translation differences	(24)
Actuarial gains and losses on defined-benefit plans	146
Ending balance	3,982
Provisions for other long-term benefits
Reconciliation of changes in other provisions [abstract]
Beginning balance	855
Increases in provisions and other liabilities	60
Provisions utilized	(66)
Reversals of unutilized provisions	0
Transfers	(1)
Net interest related to employee benefits, and unwinding of discount	1
Currency translation differences	(2)
Actuarial gains and losses on defined-benefit plans	0
Ending balance	847
Restructuring provisions
Reconciliation of changes in other provisions [abstract]
Beginning balance	600
Increases in provisions and other liabilities	531
Provisions utilized	(2)
Reversals of unutilized provisions	(21)
Transfers	(117)
Net interest related to employee benefits, and unwinding of discount	0
Currency translation differences	(3)
Actuarial gains and losses on defined-benefit plans	0
Ending balance	988
Other provisions
Reconciliation of changes in other provisions [abstract]
Beginning balance	2,071
Increases in provisions and other liabilities	149
Provisions utilized	(98)
Reversals of unutilized provisions	(78)
Transfers	(76)
Net interest related to employee benefits, and unwinding of discount	5
Currency translation differences	(22)
Actuarial gains and losses on defined-benefit plans	0
Ending balance	€ 1,951

Provisions and Other Liabilit_5

Provisions and Other Liabilities - Provisions for pensions and other post-employment benefits (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
UK \| Actuarial assumption of discount rates
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial assumption, increase (decrease) in rate	(0.50%)
UK \| Actuarial assumption of expected rates of inflation
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial assumption, increase (decrease) in rate	(0.05%)	0.05%
United States \| Actuarial assumption of discount rates
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial assumption, increase (decrease) in rate	(0.50%)
Maximum \| Actuarial assumption of discount rates
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial assumption, increase (decrease) in rate		(1.00%)
Minimum \| Actuarial assumption of discount rates
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial assumption, increase (decrease) in rate		(0.65%)
Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial gains/(losses) on benefit obligations	€ (454)	€ (1,190)	€ (1,301)
Pensions and other post-employment benefits \| Plan assets
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial gains/(losses) on plan assets	€ 308	€ 655	€ 926

Provisions and Other Liabilit_6

Provisions and Other Liabilities - Other Non-Current Liabilities (Details) - EUR (€) € in Millions	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Disclosure Of Other Non Current Liabilities [Line Items]
Non-current liabilities related to income taxes	€ 1,712	€ 1,666	€ 1,452
Other non-current liabilities	305	302	246
Total	2,017	1,968	1,698
Uncertainties over income tax treatments
Disclosure Of Other Non Current Liabilities [Line Items]
Non-current liabilities related to income taxes	€ 1,064	€ 1,031	€ 812

Provisions and Other Liabilit_7

Provisions and Other Liabilities - Additional Information (Details) $ in Millions	Dec. 31, 2019USD ($)
Subclassifications of assets, liabilities and equities [abstract]
Litigation amount payable	$ 315

Off Balance Sheet Commitments (

Off Balance Sheet Commitments (Details) € in Millions, $ in Millions	Jul. 20, 2020USD ($)shares	Jun. 30, 2020EUR (€)	Jun. 30, 2019EUR (€)	Dec. 31, 2019EUR (€)
Disclosure Of Off Balance Sheet Commitments [Line Items]
Commitments related to projects in research phase		€ 700
Commitments related to research and development payments contingent upon attainment of sales targets		600
Commitments related to potential milestone payments for projects under collaboration agreements		300
Acquisitions of other equity investments		€ 17	€ 24	€ 38
Translate Bio \| Entering into significant commitments or contingent liabilities
Disclosure Of Off Balance Sheet Commitments [Line Items]
Commitments related to potential milestone payments for projects under collaboration agreements \| $	$ 1,400
Upfront payment \| $	425
Acquisitions of other equity investments \| $	$ 95
Acquisitions of other equity investments (in shares) \| shares	4,900,000

Other Operating Income And Ex_3

Other Operating Income And Expenses - Additional Information (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	€ 281	€ 273	€ 825
Miscellaneous other operating expense	693	466	1,207
Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Miscellaneous other operating expense	482	234	681
Other operating income (expense) \| Regeneron
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	79	30	82
Commercialization related expenses \| Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Miscellaneous other operating expense	176	218	449
Income & expense related to (profit)/loss sharing of the Antibodies Alliance \| Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Miscellaneous other operating expense	341	16	253
Additional share of profit paid by Regeneron related to development costs \| Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	35	0	€ 21
Other related parties \| Other operating income (expense)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	92	36
Gains on divestment of some mature products	147	71
Other related parties \| Commercialization related expenses \| Regeneron
Disclosure Of Other Operating Income Expenses [Line Items]
Miscellaneous other operating expense	€ 525	€ 241

Other Operating Income And Ex_4

Other Operating Income And Expenses - Other Income and Expense (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure Of Other Operating Income Expenses [Line Items]
Miscellaneous other operating expense	€ (693)	€ (466)	€ (1,207)
Other operating income	281	273	825
Other operating income/(expenses), net, related to Regeneron Alliance	(446)	(211)	(633)
Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Miscellaneous other operating expense	(482)	(234)	(681)
Other
Disclosure Of Other Operating Income Expenses [Line Items]
Miscellaneous other operating expense	(8)	(7)	(14)
Immuno-Oncology Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	44	30	62
Income & expense related to (profit)/loss sharing of the Antibodies Alliance \| Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Miscellaneous other operating expense	(341)	(16)	(253)
Additional share of profit paid by Regeneron related to development costs \| Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	35	0	21
Commercialization related expenses \| Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Miscellaneous other operating expense	(176)	(218)	(449)
Regeneron \| Other operating income (expense)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	€ 79	€ 30	€ 82

Restructuring Costs And Simil_3

Restructuring Costs And Similar Items - Summary of Restructuring Costs and Similar Items (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Analysis of income and expense [abstract]
Employee-related expenses	€ 642	€ 667	€ 791
Expenses related to property, plant and equipment and to inventories	62	39	106
Compensation for early termination of contracts (other than contracts of employment)	11	3	49
Decontamination costs	0	1	27
Other restructuring costs	43	37	89
Total	€ 758	€ 747	€ 1,062

Other Gains and Losses, and L_2

Other Gains and Losses, and Litigation - Additional Information (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure of other provisions [Line Items]
Other gains and (losses) and litigation	€ 136	€ 317	€ 327
Seprafilm
Disclosure of other provisions [Line Items]
Other gains and (losses) and litigation	€ 313

Financial Expenses and Income -

Financial Expenses and Income - Summary of Analysis of Financial Income and Expenses (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure of detailed information about finance income expense [Line Items]
Cost of debt	€ (166)	€ (171)	€ (318)
Interest income	66	82	146
Cost of net debt	(100)	(89)	(172)
Non-operating foreign exchange gains/(losses)	2	3	1
Unwinding of discounting of provisions	(6)	(12)	(25)
Net interest cost related to employee benefits	(32)	(45)	(87)
Net interest expense on lease liabilities	(19)	(20)	(39)
Other	(12)	13	19
Net financial income/(expenses)	(167)	(150)	(303)
comprising: Financial expenses	(198)	(244)	(444)
Financial income	31	94	141
Interest rate and currency derivatives used to hedge debt
Disclosure of detailed information about finance income expense [Line Items]
Gain on derivatives used to manage debt	58	83	187
Gain on derivatives used to manage cash and cash equivalents	€ 37	€ 27	€ 55

Income Tax Expense - Summary of

Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Income Taxes [Abstract]
Current taxes	€ (1,127)	€ (828)	€ (1,892)
Deferred taxes	133	815	1,753
Total	(994)	(13)	(139)
Income before tax and investments accounted for using the equity method	€ 9,941	€ 962	€ 2,822

Income Tax Expense - Summary _2

Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Income Taxes [Abstract]
Standard tax rate applicable in France	3200.00%	3440.00%	3440.00%
Difference between the standard French tax rate and the rates applicable to Sanofi	(2020.00%)	(1370.00%)	(2290.00%)
Impact of commitments arising from business divestitures	0.00%	(1210.00%)	(620.00%)
Revisions to tax exposures and settlements of tax disputes	20.00%	450.00%	480.00%
Fair value remeasurement of contingent consideration liabilities	(10.00%)	(300.00%)	(260.00%)
Other	(190.00%)	(880.00%)	(260.00%)
Effective tax rate	1000.00%	130.00%	490.00%

Segment Information - Additiona

Segment Information - Additional Information (Details)	6 Months Ended
Segment Information - Additional Information (Details)	Jun. 30, 2020segmentshares	May 29, 2020shares
Disclosure of operating segments [Line Items]
Number of operating segments \| segment	3
Regeneron
Disclosure of operating segments [Line Items]
Non-current financial assets, number of shares (in shares) \| shares	279,766	400,000

Segment Information - Summary o

Segment Information - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure of geographical areas [line items]
Net sales	€ 17,180	€ 17,019	€ 36,126
Pharmaceuticals
Disclosure of geographical areas [line items]
Net sales	13,020	12,718
Pharmaceuticals \| General Medicines
Disclosure of geographical areas [line items]
Net sales	7,618	8,404
Pharmaceuticals \| Lantus
Disclosure of geographical areas [line items]
Net sales	1,417	1,532
Pharmaceuticals \| Toujeo
Disclosure of geographical areas [line items]
Net sales	496	431
Pharmaceuticals \| Praluent
Disclosure of geographical areas [line items]
Net sales	146	122
Pharmaceuticals \| Multaq
Disclosure of geographical areas [line items]
Net sales	154	161
Pharmaceuticals \| Lovenox
Disclosure of geographical areas [line items]
Net sales	630	690
Pharmaceuticals \| Plavix
Disclosure of geographical areas [line items]
Net sales	509	766
Pharmaceuticals \| Generics
Disclosure of geographical areas [line items]
Net sales	494	536
Pharmaceuticals \| Specialty Care
Disclosure of geographical areas [line items]
Net sales	5,402	4,314
Pharmaceuticals \| Aubagio
Disclosure of geographical areas [line items]
Net sales	1,068	903
Pharmaceuticals \| Cerezyme
Disclosure of geographical areas [line items]
Net sales	368	363
Pharmaceuticals \| Myozyme/Lumizyme
Disclosure of geographical areas [line items]
Net sales	472	454
Pharmaceuticals \| Fabrazyme
Disclosure of geographical areas [line items]
Net sales	413	396
Pharmaceuticals \| Eloctate
Disclosure of geographical areas [line items]
Net sales	330	345
Pharmaceuticals \| Jevtana
Disclosure of geographical areas [line items]
Net sales	271	237
Pharmaceuticals \| Dupixent
Disclosure of geographical areas [line items]
Net sales	1,634	825
Consumer Healthcare
Disclosure of geographical areas [line items]
Net sales	2,324	2,407
Consumer Healthcare \| Allergy, Cough and Cold
Disclosure of geographical areas [line items]
Net sales	640	617
Consumer Healthcare \| Pain
Disclosure of geographical areas [line items]
Net sales	635	641
Consumer Healthcare \| Digestive
Disclosure of geographical areas [line items]
Net sales	426	538
Consumer Healthcare \| Nutritionals
Disclosure of geographical areas [line items]
Net sales	308	300
Vaccines
Disclosure of geographical areas [line items]
Net sales	1,836	1,894
Vaccines \| Polio/Pertussis/Hib vaccines
Disclosure of geographical areas [line items]
Net sales	1,059	988
Vaccines \| Influenza vaccines
Disclosure of geographical areas [line items]
Net sales	179	117
Europe
Disclosure of geographical areas [line items]
Net sales	4,345	4,451
Europe \| Pharmaceuticals
Disclosure of geographical areas [line items]
Net sales	3,347	3,393
Europe \| Pharmaceuticals \| General Medicines
Disclosure of geographical areas [line items]
Net sales	2,232	2,421
Europe \| Pharmaceuticals \| Lantus
Disclosure of geographical areas [line items]
Net sales	281	306
Europe \| Pharmaceuticals \| Toujeo
Disclosure of geographical areas [line items]
Net sales	188	167
Europe \| Pharmaceuticals \| Praluent
Disclosure of geographical areas [line items]
Net sales	56	63
Europe \| Pharmaceuticals \| Multaq
Disclosure of geographical areas [line items]
Net sales	12	20
Europe \| Pharmaceuticals \| Lovenox
Disclosure of geographical areas [line items]
Net sales	298	385
Europe \| Pharmaceuticals \| Plavix
Disclosure of geographical areas [line items]
Net sales	67	70
Europe \| Pharmaceuticals \| Generics
Disclosure of geographical areas [line items]
Net sales	57	66
Europe \| Pharmaceuticals \| Specialty Care
Disclosure of geographical areas [line items]
Net sales	1,115	972
Europe \| Pharmaceuticals \| Aubagio
Disclosure of geographical areas [line items]
Net sales	231	204
Europe \| Pharmaceuticals \| Cerezyme
Disclosure of geographical areas [line items]
Net sales	125	128
Europe \| Pharmaceuticals \| Myozyme/Lumizyme
Disclosure of geographical areas [line items]
Net sales	193	195
Europe \| Pharmaceuticals \| Fabrazyme
Disclosure of geographical areas [line items]
Net sales	98	90
Europe \| Pharmaceuticals \| Eloctate
Disclosure of geographical areas [line items]
Net sales	0	0
Europe \| Pharmaceuticals \| Jevtana
Disclosure of geographical areas [line items]
Net sales	92	87
Europe \| Pharmaceuticals \| Dupixent
Disclosure of geographical areas [line items]
Net sales	174	83
Europe \| Consumer Healthcare
Disclosure of geographical areas [line items]
Net sales	717	741
Europe \| Consumer Healthcare \| Allergy, Cough and Cold
Disclosure of geographical areas [line items]
Net sales	177	184
Europe \| Consumer Healthcare \| Pain
Disclosure of geographical areas [line items]
Net sales	271	275
Europe \| Consumer Healthcare \| Digestive
Disclosure of geographical areas [line items]
Net sales	167	175
Europe \| Consumer Healthcare \| Nutritionals
Disclosure of geographical areas [line items]
Net sales	62	67
Europe \| Vaccines
Disclosure of geographical areas [line items]
Net sales	281	317
Europe \| Vaccines \| Polio/Pertussis/Hib vaccines
Disclosure of geographical areas [line items]
Net sales	162	157
Europe \| Vaccines \| Influenza vaccines
Disclosure of geographical areas [line items]
Net sales	5	2
United States
Disclosure of geographical areas [line items]
Net sales	5,880	5,401	€ 12,756
United States \| Pharmaceuticals
Disclosure of geographical areas [line items]
Net sales	4,806	4,193
United States \| Pharmaceuticals \| General Medicines
Disclosure of geographical areas [line items]
Net sales	1,458	1,647
United States \| Pharmaceuticals \| Lantus
Disclosure of geographical areas [line items]
Net sales	474	568
United States \| Pharmaceuticals \| Toujeo
Disclosure of geographical areas [line items]
Net sales	143	139
United States \| Pharmaceuticals \| Praluent
Disclosure of geographical areas [line items]
Net sales	68	44
United States \| Pharmaceuticals \| Multaq
Disclosure of geographical areas [line items]
Net sales	135	135
United States \| Pharmaceuticals \| Lovenox
Disclosure of geographical areas [line items]
Net sales	15	18
United States \| Pharmaceuticals \| Plavix
Disclosure of geographical areas [line items]
Net sales	5	0
United States \| Pharmaceuticals \| Generics
Disclosure of geographical areas [line items]
Net sales	75	79
United States \| Pharmaceuticals \| Specialty Care
Disclosure of geographical areas [line items]
Net sales	3,348	2,546
United States \| Pharmaceuticals \| Aubagio
Disclosure of geographical areas [line items]
Net sales	775	645
United States \| Pharmaceuticals \| Cerezyme
Disclosure of geographical areas [line items]
Net sales	90	88
United States \| Pharmaceuticals \| Myozyme/Lumizyme
Disclosure of geographical areas [line items]
Net sales	178	162
United States \| Pharmaceuticals \| Fabrazyme
Disclosure of geographical areas [line items]
Net sales	206	199
United States \| Pharmaceuticals \| Eloctate
Disclosure of geographical areas [line items]
Net sales	234	272
United States \| Pharmaceuticals \| Jevtana
Disclosure of geographical areas [line items]
Net sales	123	101
United States \| Pharmaceuticals \| Dupixent
Disclosure of geographical areas [line items]
Net sales	1,310	669
United States \| Consumer Healthcare
Disclosure of geographical areas [line items]
Net sales	583	599
United States \| Consumer Healthcare \| Allergy, Cough and Cold
Disclosure of geographical areas [line items]
Net sales	214	187
United States \| Consumer Healthcare \| Pain
Disclosure of geographical areas [line items]
Net sales	98	93
United States \| Consumer Healthcare \| Digestive
Disclosure of geographical areas [line items]
Net sales	38	103
United States \| Consumer Healthcare \| Nutritionals
Disclosure of geographical areas [line items]
Net sales	23	19
United States \| Vaccines
Disclosure of geographical areas [line items]
Net sales	491	609
United States \| Vaccines \| Polio/Pertussis/Hib vaccines
Disclosure of geographical areas [line items]
Net sales	183	192
United States \| Vaccines \| Influenza vaccines
Disclosure of geographical areas [line items]
Net sales	13	4
Other countries
Disclosure of geographical areas [line items]
Net sales	6,955	7,167
Other countries \| Pharmaceuticals
Disclosure of geographical areas [line items]
Net sales	4,867	5,132
Other countries \| Pharmaceuticals \| General Medicines
Disclosure of geographical areas [line items]
Net sales	3,928	4,336
Other countries \| Pharmaceuticals \| Lantus
Disclosure of geographical areas [line items]
Net sales	662	658
Other countries \| Pharmaceuticals \| Toujeo
Disclosure of geographical areas [line items]
Net sales	165	125
Other countries \| Pharmaceuticals \| Praluent
Disclosure of geographical areas [line items]
Net sales	22	15
Other countries \| Pharmaceuticals \| Multaq
Disclosure of geographical areas [line items]
Net sales	7	6
Other countries \| Pharmaceuticals \| Lovenox
Disclosure of geographical areas [line items]
Net sales	317	287
Other countries \| Pharmaceuticals \| Plavix
Disclosure of geographical areas [line items]
Net sales	437	696
Other countries \| Pharmaceuticals \| Generics
Disclosure of geographical areas [line items]
Net sales	362	391
Other countries \| Pharmaceuticals \| Specialty Care
Disclosure of geographical areas [line items]
Net sales	939	796
Other countries \| Pharmaceuticals \| Aubagio
Disclosure of geographical areas [line items]
Net sales	62	54
Other countries \| Pharmaceuticals \| Cerezyme
Disclosure of geographical areas [line items]
Net sales	153	147
Other countries \| Pharmaceuticals \| Myozyme/Lumizyme
Disclosure of geographical areas [line items]
Net sales	101	97
Other countries \| Pharmaceuticals \| Fabrazyme
Disclosure of geographical areas [line items]
Net sales	109	107
Other countries \| Pharmaceuticals \| Eloctate
Disclosure of geographical areas [line items]
Net sales	96	73
Other countries \| Pharmaceuticals \| Jevtana
Disclosure of geographical areas [line items]
Net sales	56	49
Other countries \| Pharmaceuticals \| Dupixent
Disclosure of geographical areas [line items]
Net sales	150	73
Other countries \| Consumer Healthcare
Disclosure of geographical areas [line items]
Net sales	1,024	1,067
Other countries \| Consumer Healthcare \| Allergy, Cough and Cold
Disclosure of geographical areas [line items]
Net sales	249	246
Other countries \| Consumer Healthcare \| Pain
Disclosure of geographical areas [line items]
Net sales	266	273
Other countries \| Consumer Healthcare \| Digestive
Disclosure of geographical areas [line items]
Net sales	221	260
Other countries \| Consumer Healthcare \| Nutritionals
Disclosure of geographical areas [line items]
Net sales	223	214
Other countries \| Vaccines
Disclosure of geographical areas [line items]
Net sales	1,064	968
Other countries \| Vaccines \| Polio/Pertussis/Hib vaccines
Disclosure of geographical areas [line items]
Net sales	714	639
Other countries \| Vaccines \| Influenza vaccines
Disclosure of geographical areas [line items]
Net sales	€ 161	€ 111

Segment Information - Schedule

Segment Information - Schedule of Segment Results (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure of operating segments [Line Items]
Net sales	€ 17,180	€ 17,019	€ 36,126
Other revenues	574	674	1,505
Cost of sales	(5,543)	(5,385)	(11,976)
Research and development expenses	(2,692)	(2,972)	(6,018)
Selling and general expenses	(4,607)	(4,835)	(9,883)
Net income attributable to non-controlling interests	20	15	31
Pharmaceuticals
Disclosure of operating segments [Line Items]
Net sales	13,020	12,718
Consumer Healthcare
Disclosure of operating segments [Line Items]
Net sales	2,324	2,407
Vaccines
Disclosure of operating segments [Line Items]
Net sales	1,836	1,894
New segment reporting model \| Pharmaceuticals
Disclosure of operating segments [Line Items]
Net sales	13,020	12,718	25,700
Other revenues	70	103	173
Cost of sales	(3,427)	(3,239)	(6,750)
Research and development expenses	(2,143)	(2,423)	(4,850)
Selling and general expenses	(2,472)	(2,679)	(5,442)
Other operating income and expenses	(150)	(228)	(625)
Share of profit (loss) of associates and joint ventures accounted for using equity method	4	4	5
Net income attributable to non-controlling interests	(17)	(12)	(29)
Business operating income	4,885	4,244	8,182
New segment reporting model \| Consumer Healthcare
Disclosure of operating segments [Line Items]
Net sales	2,324	2,407	4,695
Other revenues	30	27	57
Cost of sales	(770)	(783)	(1,599)
Research and development expenses	(61)	(71)	(149)
Selling and general expenses	(760)	(760)	(1,529)
Other operating income and expenses	21	105	193
Share of profit (loss) of associates and joint ventures accounted for using equity method	7	6	(5)
Net income attributable to non-controlling interests	(4)	(3)	(6)
Business operating income	787	928	1,657
New segment reporting model \| Vaccines
Disclosure of operating segments [Line Items]
Net sales	1,836	1,894	5,731
Other revenues	474	544	1,275
Cost of sales	(1,184)	(1,255)	(3,372)
Research and development expenses	(324)	(295)	(639)
Selling and general expenses	(386)	(374)	(823)
Other operating income and expenses	4	(6)	0
Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	9
Net income attributable to non-controlling interests	0	0	0
Business operating income	420	508	2,181
New segment reporting model \| Other
Disclosure of operating segments [Line Items]
Net sales	0	0	0
Other revenues	0	0	0
Cost of sales	(126)	(105)	(252)
Research and development expenses	(164)	(183)	(380)
Selling and general expenses	(989)	(1,022)	(2,089)
Other operating income and expenses	(130)	(64)	50
Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	0
Net income attributable to non-controlling interests	0	0	0
Business operating income	(1,409)	(1,374)	(2,671)
New segment reporting model \| Total Sanofi
Disclosure of operating segments [Line Items]
Net sales	17,180	17,019	36,126
Other revenues	574	674	1,505
Cost of sales	(5,507)	(5,382)	(11,973)
Research and development expenses	(2,692)	(2,972)	(6,018)
Selling and general expenses	(4,607)	(4,835)	(9,883)
Other operating income and expenses	(255)	(193)	(382)
Share of profit (loss) of associates and joint ventures accounted for using equity method	11	10	9
Net income attributable to non-controlling interests	(21)	(15)	(35)
Business operating income	€ 4,683	€ 4,306	€ 9,349

Segment Information - Schedul_2

Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) - EUR (€) € in Millions	May 29, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure of operating segments [Line Items]
Net income attributable to non-controlling interests		€ 20	€ 15	€ 31
Fair value remeasurement of contingent consideration		54	190	238
Restructuring costs and similar items		(758)	(747)	(1,062)
Other gains and losses, and litigation		136	317	327
Gain on Regeneron investment arising from transaction of May 29, 2020		7,382	0	0
Operating income		10,108	1,112	3,125
Financial expenses		(198)	(244)	(444)
Financial income		31	94	141
Income before tax and investments accounted for using the equity method		€ 9,941	962	2,822
Regeneron
Disclosure of operating segments [Line Items]
Gain on Regeneron investment arising from transaction of May 29, 2020	€ 7,382
Sale of stock, number of shares issued in transaction (in shares)	22,800,000
Non-current financial assets, number of shares (in shares)	400,000	279,766
Regeneron \| Public Offering
Disclosure of operating segments [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	13,000,000
Regeneron \| Private Placement \| Regeneron Pharmaceuticals, Inc
Disclosure of operating segments [Line Items]
Regeneron ordinary shares sold to regeneron	9,800,000
Operating segments
Disclosure of operating segments [Line Items]
Business operating income		€ 4,683	4,306	9,349
Operating segments \| Regeneron
Disclosure of operating segments [Line Items]
Business operating income			159	411
Material reconciling items
Disclosure of operating segments [Line Items]
Share of profit (loss) of associates and joint ventures accounted for using equity method		(11)	(10)	(9)
Net income attributable to non-controlling interests		21	15	35
Amortization and impairment of intangible assets		(1,206)	(2,956)	(5,750)
Fair value remeasurement of contingent consideration		54	190	238
Expenses arising from the impact of acquisitions on inventories		(36)	(3)	(3)
Restructuring costs and similar items		(758)	(747)	(1,062)
Other gains and losses, and litigation		136	317	327
Gain on Regeneron investment arising from transaction of May 29, 2020		€ 7,225	€ 0	€ 0

Segment Information - Schedul_3

Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details) - New segment reporting model - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Pharmaceuticals
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method	€ 149	€ 327	€ 205
Acquisitions of property, plant and equipment	294	383	773
Acquisitions of other intangible assets	153	124	321
Consumer Healthcare
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method	3	20	4
Acquisitions of property, plant and equipment	27	28	88
Acquisitions of other intangible assets	6	7	51
Vaccines
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method	44	32	40
Acquisitions of property, plant and equipment	181	243	462
Acquisitions of other intangible assets	21	56	121
Reportable segments
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method	196	379	249
Acquisitions of property, plant and equipment	502	654	1,323
Acquisitions of other intangible assets	€ 180	€ 187	€ 493

Segment Information - Summary_2

Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Disclosure of geographical areas [line items]
Net sales	€ 17,180	€ 17,019	€ 36,126
Property, plant and equipment	9,368		9,717
goodwill	45,254		44,519
Other intangible assets	17,021		16,572
Reportable geographical zones
Disclosure of geographical areas [line items]
Net sales	17,180	17,019	36,126
Property, plant and equipment	9,368	9,606	9,717
goodwill	45,254	44,418	44,519
Other intangible assets	17,021	19,098	16,572
Europe
Disclosure of geographical areas [line items]
Net sales	4,345	4,351	8,852
Property, plant and equipment	5,683	5,781	5,824
goodwill	0	0	0
Other intangible assets	6,544	7,439	6,941
France
Disclosure of geographical areas [line items]
Net sales	1,061	1,099	2,261
Property, plant and equipment	3,067	3,120	3,141
goodwill	0	0	0
Other intangible assets	0	0	0
North America
Disclosure of geographical areas [line items]
Net sales	6,151	5,685	13,370
Property, plant and equipment	2,756	2,791	2,862
goodwill	0	0	0
Other intangible assets	8,838	9,485	7,825
United States
Disclosure of geographical areas [line items]
Net sales	5,880	5,401	12,756
Property, plant and equipment	2,153	2,250	2,264
goodwill	0	0	0
Other intangible assets	0	0	0
Other countries
Disclosure of geographical areas [line items]
Net sales	6,684	6,983	13,904
Property, plant and equipment	929	1,034	1,031
goodwill	0	0	0
Other intangible assets	€ 1,639	€ 2,174	€ 1,806

Segment Information - Principal

Segment Information - Principal Customers and Credit Risk (Details)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Customer one
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	9.00%	9.00%
Customer two
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	6.00%	6.00%
Customer three
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	5.00%	4.00%

Events subsequent to June 30,_2

Events subsequent to June 30, 2020 (Details) € in Millions, $ in Millions	Jul. 09, 2020USD ($)	Jul. 08, 2020EUR (€)	Jun. 30, 2020EUR (€)
Disclosure of non-adjusting events after reporting period [line items]
Commitments related to potential milestone payments for projects under collaboration agreements			€ 300
Kiadis Pharma N.V. \| Entering into significant commitments or contingent liabilities
Disclosure of non-adjusting events after reporting period [line items]
Upfront payment		€ 17.5
Commitments related to potential milestone payments for projects under collaboration agreements		€ 857.5
Kymera Therapeutics Inc. \| Entering into significant commitments or contingent liabilities
Disclosure of non-adjusting events after reporting period [line items]
Upfront payment \| $	$ 150
Commitments related to potential milestone payments for projects under collaboration agreements \| $	$ 2,000